[
  {
    "sentence": "Among these RTKs, there are epidermal growth factor receptors (EGFRs), vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), insulin-like growth factor receptors (IGFRs) and FGFRs [6] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Upon ligand stimulation, RTKs activate several pathways, including mitogen-activated protein kinase (MAPK), Janus kinase (JAK)/signal transducer and activator of transcription (STAT), phospholipase C gamma (PLCγ) and phosphoinositide 3-kinase (PI3–K) [7] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RTK signalling regulates the response of cancer cells to perturbation of the extracellular environment, composed of fibroblasts, adipocytes, immune cells, and proteins of the extracellular matrix and of the extended vasculature [8] (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The different subfamilies are based on the biochemical properties, sequence similarities and evolutionary relationships of their members (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Firstly, Y653, in the activation loop, is phosphorylated, followed by the phosphorylation of Y583, Y463, Y654, Y677, Y766 and Y585, whereas Y730 is weakly phosphorylated [11–13] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FRS2α, which is constitutively associated with the receptor, is phosphorylated upon ligand binding, and recruits adaptor proteins, like GRB2, which in turn recruits SOS followed by members of the MAPK family, and GAB1, which then activates the PI3K–AKT signalling axis [15] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "By contrast, AKT induces the activation of the mTOR complex 1 [22] and the phosphorylation of the FOXO1 transcription factor [23] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Following recruitment to activated FGFR the enzyme PLCγ induces calcium ion release, resulting in the activation of downstream kinases like PKC [24] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR also activates STAT1, 3 and 5, which regulate gene expression in the nucleus [25] (figure 2c).3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFs, FGFRs and cofactors\nThe FGF family includes secreted FGFs—the FGF1, FGF4, FGF7, FGF8, FGF9 and FGF15/19 subfamilies—and intracellular FGFs—the FGF11 subfamily [26,27] (figure 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs—also known as FGF homologous factors (FHFs) (figure 2a)—serve as cofactors for members of the voltage-gated sodium channel family, mitogen-activated protein kinase 8-interacting protein 2 (MAPK8IP2), β-tubulin and NF-κB essential modulator (NEMO) [40–43].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are five FGFR genes, and FGFR1–3 can be alternatively spliced into variants of immunoglobulin-like domain III, referred to as ‘b’ and ‘c’, which are essential for ligand-binding specificity and are mainly expressed in epithelial and mesenchymal cells, respectively [4,45–47] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR1c and 3c interact with FGF2, members of the FGF4, 8 and 9 subfamilies, and with the endocrine FGFs (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR2c can bind the same FGFs as the other two mesenchymal isoforms of FGFR with the exception of the endocrine FGFs FGF21 and FGF23 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The epithelial isoforms of FGFR1 and 2, FGFR1b and 2b, are preferentially activated by the FGF7 subfamily—with FGF7 specific for FGFR2b, whereas FGFR3b interacts with the FGF8 and 9 subfamilies [49,50] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The endocrine FGF15/19 subfamily has higher affinity for the mesenchymal isoforms of FGFR1–3 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR4 is activated not only upon FGF2, 4, 6, 8, 17 and 18 binding but also by the endocrine ligands FGF15/19 and FGF23 [51] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regulatory mechanisms may occur at different levels: in the extracellular environment, at the plasma membrane, during internalization and sorting or translocation to the nucleus, and through feedback signalling mechanisms (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Other cell surface molecules, like anosmin-1, Similar Expression to Fgf (SEF), and the adhesion molecules N-cadherin or Neuronal Cell Adhesion Molecule (NCAM), can modulate FGFR signalling in different cell contexts and organs [63–67], thus enlarging the variety of extracellular modulator of FGFR signalling [10] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Similarities and differences in signalling of the four FGFRs could be also determined by sub-cellular localization (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, nuclear translocation of FGFR1 and FGFR2 has been shown to specify the behaviour of cancer cells by regulating signalling and transcription [73,74], thus adding a further layer of complexity in the regulation of FGFR activity (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SPROUTY interacts with GRB2 to regulate the activation of MAPK and PI3K–AKT downstream from FGFR phosphorylation [77,78] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Finally, the E3 ubiquitin ligase CBL induces the ubiquitylation of FGFR after receptor internalization and regulates the sorting of FGFR into the degradative pathway which results in signalling termination [81] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in Fgf10 knock-out mice this defect is less pronounced, owing to the redundant expression of another FGFR2b-specific ligand, FGF7 [31] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the mammary gland epithelium fails to ramify in the Fgf10 knock-out mice, where an underdeveloped mammary fat pad has also been observed [31], suggesting a role for FGF10 in the formation of adipocytes via FGFR1b signalling [86] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the several FGFs produced by the mammary gland stroma, including FGF2, FGF7, FGF9 and FGF10, regulate epithelial morphogenesis through FGFR1 and FGFR2 activation [88] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This ductal/ lobular cellular bilayer is encapsulated by the diverse cell types (immune and non-immune) of the tumour microenvironment (TME) and stromal tissue (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "10%)), using laboratory-based immunohistochemistry and/or in situ hybridization assays based on differential expression of oestrogen, progesterone and the HER2 receptor (ER, PR and HER2) (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Activation of FGFRs in breast cancer is attributed to receptor gene amplification and mutations, gene fusions resulting from translocations and amplification, and more rarely alternative splicing [3] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Schematic of breast cancer extracellular environment (from figure 1) and breast cancer epithelial cells (from figures 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The black lines on the ‘FGF’ text indicate the lack of available information on the role of those specific FGFs in breast cancer.Numerous FGF genes are amplified or show deregulated levels of transcripts and proteins and are often overexpressed in the extracellular matrix or in the stroma, all mechanisms contributing to the amplification of FGFR signalling or the inhibition of its regulatory mechanisms [113] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We will highlight their known genetic alterations, and discuss how dysregulated signalling pathways and cellular localization, and interactions with the microenvironment globally affect the behaviour of breast cancer cells (figure 4).5.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF1 subfamily: FGF1, FGF2\nThe FGF1 subfamily is composed of FGF1 (also known as acidic FGF) and of FGF2 (also known as basic FGF) (figure 2a,b), which have minor roles during development, but are crucial for tissue repair after injury in the adult and in angiogenesis [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF2 regulates tumour growth and migration in vitro and in xenograft models [125], not only by activating FGFR1 signalling [126], but also through oestrogen receptor (ER) signalling [127] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Both FGF1 and FGF2 play a crucial role in breast cancer angiogenesis [129,130] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF4 subfamily: FGF4, FGF5, FGF6\nThe FGF4 subfamily is composed of FGF4, which is crucial for early development in mice, FGF5 and FGF6, whose deletion in mice does not have a known phenotype [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF7 subfamily: FGF3, FGF7, FGF10, FGF22\nMembers of the FGF7 subfamily are FGF3, FGF7, FGF10 and FGF22 (figure 2a,b), of which FGF10 is known to be involved in the formation of mammary gland during development [2] (see §4.2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, anti-FGF3/FGFR2b therapies may benefit patients with HER2-positive breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In terms of signalling pathway activation, FGF7 binding to its receptor FGFR2b (figure 2b) also activates ERK1/2, which in turn promotes FGF7-dependent migration of ER-positive breast cancer cells [150].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF10 is also expressed exclusively by the stromal fibroblasts of normal and breast cancer tissue and has been reported to be an oncogene in mammary tumour virus mouse models and in a subset of breast carcinomas showing high expression of the protein [153,154] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This is due to the paracrine action of FGF10 on its receptor, the FGFR2b isoform, which is highly abundant on the mammary gland [157] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF8 subfamily: FGF8, FGF17, FGF18\nThe FGF8 subfamily is composed of FGF8, FGF17 and FGF18 (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF9 subfamily: FGF9, FGF16, FGF20\nMembers of the FGF9 subfamily (FGF9, FGF16, FGF20 (figure 2a,b)) regulate development at multiple levels in lungs, male germ cells, skeleton, small intestine and cardiomyocytes [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF9 is highly expressed in breast cancer compared with normal tissue, although its expression is not as high as the expression of other FGFs like FGF1 [134] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The endocrine FGFs: FGF15/19, FGF21, FGF23\nThe endocrine FGFs have several roles both during development and in the homeostasis of adult tissues [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Given the role of FGF21 in metabolism and the important relationship between metabolism and breast cancer [172], it has been suggested that monitoring the serum levels of FGF21 during anti-breast cancer therapies could be valuable, although more data are necessary to shed light on the role of FGF21 in breast cancer [173] (figure 4).5.3.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs: FGF11, FGF12, FGF13, FGF14\nMice knocked-out for intracellular FGFs (figure 2a,b) present various defects in neurons (Fgf13 and Fgf14 knock-out) and altered voltage-gated sodium channel physiology (Fgf14 knock-out) [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the same lines, the expression of a long non-coding RNA, FGF14 antisense RNA 2, was downregulated in breast compared with normal tissue, and this correlates with larger tumour size and more lymph node metastasis [175] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In vivo, resistance to CDK4/6 and to anti-HER2 treatment inhibitors can be reversed by combination with anti-FGFR drugs, such as lucitanib or erdafitinib [136,184]; this indicates the importance of targeting different pathways in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This may represent one of the mechanisms responsible for acquired resistance to the anti-HER2 drug lapatinib [187], and this finding suggests that inhibiting both FGFR1 and HER2 signalling might be beneficial for patients (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR1 signalling associated with ER in the nuclei of breast cancer cells regulates the transcription of ER-dependent genes, contributing to mechanisms of resistance in ER-positive samples [191] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The crosstalk between FGFR1 and other signalling pathways in responding to changes of the environment is also exemplified by data showing that the inhibition of both FGFR1 and VEGFR is more efficient in reducing tumour angiogenesis than either treatment alone [197,198] (figure 4).6.2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, very recently it has been reported that FGFR2 can be expressed also in ER/PR-positive tumours where, surprisingly, low FGFR2 expression correlates with poor prognosis [201] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the signalling cascades activated by FGF10 downstream of FGFR2b were reported to counteract ER-dependent signalling [156] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR2 signalling promotes HER2 shedding through the metalloprotease ADAM10 and enhances HER2 signalling, HER2-dependent proliferation and tumour progression in mouse xenografts [216] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the authors showed that FGF5 secreted by cancer-associated fibroblasts (CAF) in the microenvironment might be responsible for the high activation of FGFR2 on the neighbouring epithelial cells [137], confirming the potential signalling switch between HER2 and FGFR2 in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF7, another specific ligand for FGFR2b (figure 2a,b) has been shown to trigger phosphorylation of progesterone receptor at Ser294 and its degradation via the FGFR2–RSK2 signalling axis [151].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A potential mechanism underlying this effect is FGFR4-mediated regulation of membrane ruffling in response to both FGF1 and 2 [122] (figure 2a,b), which might increase AKT signalling.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The role of FGFR4 in liver metabolism may offer an alternative explanation to link AKT signalling and survival depending on FGFR4 signalling [222] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Given the variety of phenotypes of mice knocked-out for Fgfr isoforms [4], the differential expression and role of the ‘b’ and ‘c’ variants in tissue [61], and the possibility of trans-phosphorylation between different FGFRs [245], it is worth speculating that the landscape of dysregulated FGFR signalling is much more complex than the one presented here (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Among these RTKs, there are epidermal growth factor receptors (EGFRs), vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), insulin-like growth factor receptors (IGFRs) and FGFRs [6] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Upon ligand stimulation, RTKs activate several pathways, including mitogen-activated protein kinase (MAPK), Janus kinase (JAK)/signal transducer and activator of transcription (STAT), phospholipase C gamma (PLCγ) and phosphoinositide 3-kinase (PI3–K) [7] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RTK signalling regulates the response of cancer cells to perturbation of the extracellular environment, composed of fibroblasts, adipocytes, immune cells, and proteins of the extracellular matrix and of the extended vasculature [8] (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The different subfamilies are based on the biochemical properties, sequence similarities and evolutionary relationships of their members (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Firstly, Y653, in the activation loop, is phosphorylated, followed by the phosphorylation of Y583, Y463, Y654, Y677, Y766 and Y585, whereas Y730 is weakly phosphorylated [11–13] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FRS2α, which is constitutively associated with the receptor, is phosphorylated upon ligand binding, and recruits adaptor proteins, like GRB2, which in turn recruits SOS followed by members of the MAPK family, and GAB1, which then activates the PI3K–AKT signalling axis [15] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "By contrast, AKT induces the activation of the mTOR complex 1 [22] and the phosphorylation of the FOXO1 transcription factor [23] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Following recruitment to activated FGFR the enzyme PLCγ induces calcium ion release, resulting in the activation of downstream kinases like PKC [24] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR also activates STAT1, 3 and 5, which regulate gene expression in the nucleus [25] (figure 2c).3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFs, FGFRs and cofactors\nThe FGF family includes secreted FGFs—the FGF1, FGF4, FGF7, FGF8, FGF9 and FGF15/19 subfamilies—and intracellular FGFs—the FGF11 subfamily [26,27] (figure 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs—also known as FGF homologous factors (FHFs) (figure 2a)—serve as cofactors for members of the voltage-gated sodium channel family, mitogen-activated protein kinase 8-interacting protein 2 (MAPK8IP2), β-tubulin and NF-κB essential modulator (NEMO) [40–43].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are five FGFR genes, and FGFR1–3 can be alternatively spliced into variants of immunoglobulin-like domain III, referred to as ‘b’ and ‘c’, which are essential for ligand-binding specificity and are mainly expressed in epithelial and mesenchymal cells, respectively [4,45–47] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR1c and 3c interact with FGF2, members of the FGF4, 8 and 9 subfamilies, and with the endocrine FGFs (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR2c can bind the same FGFs as the other two mesenchymal isoforms of FGFR with the exception of the endocrine FGFs FGF21 and FGF23 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The epithelial isoforms of FGFR1 and 2, FGFR1b and 2b, are preferentially activated by the FGF7 subfamily—with FGF7 specific for FGFR2b, whereas FGFR3b interacts with the FGF8 and 9 subfamilies [49,50] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The endocrine FGF15/19 subfamily has higher affinity for the mesenchymal isoforms of FGFR1–3 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR4 is activated not only upon FGF2, 4, 6, 8, 17 and 18 binding but also by the endocrine ligands FGF15/19 and FGF23 [51] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regulatory mechanisms may occur at different levels: in the extracellular environment, at the plasma membrane, during internalization and sorting or translocation to the nucleus, and through feedback signalling mechanisms (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Other cell surface molecules, like anosmin-1, Similar Expression to Fgf (SEF), and the adhesion molecules N-cadherin or Neuronal Cell Adhesion Molecule (NCAM), can modulate FGFR signalling in different cell contexts and organs [63–67], thus enlarging the variety of extracellular modulator of FGFR signalling [10] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Similarities and differences in signalling of the four FGFRs could be also determined by sub-cellular localization (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, nuclear translocation of FGFR1 and FGFR2 has been shown to specify the behaviour of cancer cells by regulating signalling and transcription [73,74], thus adding a further layer of complexity in the regulation of FGFR activity (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SPROUTY interacts with GRB2 to regulate the activation of MAPK and PI3K–AKT downstream from FGFR phosphorylation [77,78] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Finally, the E3 ubiquitin ligase CBL induces the ubiquitylation of FGFR after receptor internalization and regulates the sorting of FGFR into the degradative pathway which results in signalling termination [81] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in Fgf10 knock-out mice this defect is less pronounced, owing to the redundant expression of another FGFR2b-specific ligand, FGF7 [31] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the mammary gland epithelium fails to ramify in the Fgf10 knock-out mice, where an underdeveloped mammary fat pad has also been observed [31], suggesting a role for FGF10 in the formation of adipocytes via FGFR1b signalling [86] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the several FGFs produced by the mammary gland stroma, including FGF2, FGF7, FGF9 and FGF10, regulate epithelial morphogenesis through FGFR1 and FGFR2 activation [88] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This ductal/ lobular cellular bilayer is encapsulated by the diverse cell types (immune and non-immune) of the tumour microenvironment (TME) and stromal tissue (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "10%)), using laboratory-based immunohistochemistry and/or in situ hybridization assays based on differential expression of oestrogen, progesterone and the HER2 receptor (ER, PR and HER2) (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Activation of FGFRs in breast cancer is attributed to receptor gene amplification and mutations, gene fusions resulting from translocations and amplification, and more rarely alternative splicing [3] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Schematic of breast cancer extracellular environment (from figure 1) and breast cancer epithelial cells (from figures 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The black lines on the ‘FGF’ text indicate the lack of available information on the role of those specific FGFs in breast cancer.Numerous FGF genes are amplified or show deregulated levels of transcripts and proteins and are often overexpressed in the extracellular matrix or in the stroma, all mechanisms contributing to the amplification of FGFR signalling or the inhibition of its regulatory mechanisms [113] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We will highlight their known genetic alterations, and discuss how dysregulated signalling pathways and cellular localization, and interactions with the microenvironment globally affect the behaviour of breast cancer cells (figure 4).5.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF1 subfamily: FGF1, FGF2\nThe FGF1 subfamily is composed of FGF1 (also known as acidic FGF) and of FGF2 (also known as basic FGF) (figure 2a,b), which have minor roles during development, but are crucial for tissue repair after injury in the adult and in angiogenesis [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF2 regulates tumour growth and migration in vitro and in xenograft models [125], not only by activating FGFR1 signalling [126], but also through oestrogen receptor (ER) signalling [127] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Both FGF1 and FGF2 play a crucial role in breast cancer angiogenesis [129,130] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF4 subfamily: FGF4, FGF5, FGF6\nThe FGF4 subfamily is composed of FGF4, which is crucial for early development in mice, FGF5 and FGF6, whose deletion in mice does not have a known phenotype [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF7 subfamily: FGF3, FGF7, FGF10, FGF22\nMembers of the FGF7 subfamily are FGF3, FGF7, FGF10 and FGF22 (figure 2a,b), of which FGF10 is known to be involved in the formation of mammary gland during development [2] (see §4.2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, anti-FGF3/FGFR2b therapies may benefit patients with HER2-positive breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In terms of signalling pathway activation, FGF7 binding to its receptor FGFR2b (figure 2b) also activates ERK1/2, which in turn promotes FGF7-dependent migration of ER-positive breast cancer cells [150].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF10 is also expressed exclusively by the stromal fibroblasts of normal and breast cancer tissue and has been reported to be an oncogene in mammary tumour virus mouse models and in a subset of breast carcinomas showing high expression of the protein [153,154] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This is due to the paracrine action of FGF10 on its receptor, the FGFR2b isoform, which is highly abundant on the mammary gland [157] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF8 subfamily: FGF8, FGF17, FGF18\nThe FGF8 subfamily is composed of FGF8, FGF17 and FGF18 (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF9 subfamily: FGF9, FGF16, FGF20\nMembers of the FGF9 subfamily (FGF9, FGF16, FGF20 (figure 2a,b)) regulate development at multiple levels in lungs, male germ cells, skeleton, small intestine and cardiomyocytes [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF9 is highly expressed in breast cancer compared with normal tissue, although its expression is not as high as the expression of other FGFs like FGF1 [134] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The endocrine FGFs: FGF15/19, FGF21, FGF23\nThe endocrine FGFs have several roles both during development and in the homeostasis of adult tissues [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Given the role of FGF21 in metabolism and the important relationship between metabolism and breast cancer [172], it has been suggested that monitoring the serum levels of FGF21 during anti-breast cancer therapies could be valuable, although more data are necessary to shed light on the role of FGF21 in breast cancer [173] (figure 4).5.3.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs: FGF11, FGF12, FGF13, FGF14\nMice knocked-out for intracellular FGFs (figure 2a,b) present various defects in neurons (Fgf13 and Fgf14 knock-out) and altered voltage-gated sodium channel physiology (Fgf14 knock-out) [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the same lines, the expression of a long non-coding RNA, FGF14 antisense RNA 2, was downregulated in breast compared with normal tissue, and this correlates with larger tumour size and more lymph node metastasis [175] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In vivo, resistance to CDK4/6 and to anti-HER2 treatment inhibitors can be reversed by combination with anti-FGFR drugs, such as lucitanib or erdafitinib [136,184]; this indicates the importance of targeting different pathways in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This may represent one of the mechanisms responsible for acquired resistance to the anti-HER2 drug lapatinib [187], and this finding suggests that inhibiting both FGFR1 and HER2 signalling might be beneficial for patients (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR1 signalling associated with ER in the nuclei of breast cancer cells regulates the transcription of ER-dependent genes, contributing to mechanisms of resistance in ER-positive samples [191] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The crosstalk between FGFR1 and other signalling pathways in responding to changes of the environment is also exemplified by data showing that the inhibition of both FGFR1 and VEGFR is more efficient in reducing tumour angiogenesis than either treatment alone [197,198] (figure 4).6.2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, very recently it has been reported that FGFR2 can be expressed also in ER/PR-positive tumours where, surprisingly, low FGFR2 expression correlates with poor prognosis [201] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the signalling cascades activated by FGF10 downstream of FGFR2b were reported to counteract ER-dependent signalling [156] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR2 signalling promotes HER2 shedding through the metalloprotease ADAM10 and enhances HER2 signalling, HER2-dependent proliferation and tumour progression in mouse xenografts [216] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the authors showed that FGF5 secreted by cancer-associated fibroblasts (CAF) in the microenvironment might be responsible for the high activation of FGFR2 on the neighbouring epithelial cells [137], confirming the potential signalling switch between HER2 and FGFR2 in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF7, another specific ligand for FGFR2b (figure 2a,b) has been shown to trigger phosphorylation of progesterone receptor at Ser294 and its degradation via the FGFR2–RSK2 signalling axis [151].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A potential mechanism underlying this effect is FGFR4-mediated regulation of membrane ruffling in response to both FGF1 and 2 [122] (figure 2a,b), which might increase AKT signalling.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The role of FGFR4 in liver metabolism may offer an alternative explanation to link AKT signalling and survival depending on FGFR4 signalling [222] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Given the variety of phenotypes of mice knocked-out for Fgfr isoforms [4], the differential expression and role of the ‘b’ and ‘c’ variants in tissue [61], and the possibility of trans-phosphorylation between different FGFRs [245], it is worth speculating that the landscape of dysregulated FGFR signalling is much more complex than the one presented here (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Among these RTKs, there are epidermal growth factor receptors (EGFRs), vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), insulin-like growth factor receptors (IGFRs) and FGFRs [6] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Upon ligand stimulation, RTKs activate several pathways, including mitogen-activated protein kinase (MAPK), Janus kinase (JAK)/signal transducer and activator of transcription (STAT), phospholipase C gamma (PLCγ) and phosphoinositide 3-kinase (PI3–K) [7] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RTK signalling regulates the response of cancer cells to perturbation of the extracellular environment, composed of fibroblasts, adipocytes, immune cells, and proteins of the extracellular matrix and of the extended vasculature [8] (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The different subfamilies are based on the biochemical properties, sequence similarities and evolutionary relationships of their members (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Firstly, Y653, in the activation loop, is phosphorylated, followed by the phosphorylation of Y583, Y463, Y654, Y677, Y766 and Y585, whereas Y730 is weakly phosphorylated [11–13] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FRS2α, which is constitutively associated with the receptor, is phosphorylated upon ligand binding, and recruits adaptor proteins, like GRB2, which in turn recruits SOS followed by members of the MAPK family, and GAB1, which then activates the PI3K–AKT signalling axis [15] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "By contrast, AKT induces the activation of the mTOR complex 1 [22] and the phosphorylation of the FOXO1 transcription factor [23] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Following recruitment to activated FGFR the enzyme PLCγ induces calcium ion release, resulting in the activation of downstream kinases like PKC [24] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR also activates STAT1, 3 and 5, which regulate gene expression in the nucleus [25] (figure 2c).3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFs, FGFRs and cofactors\nThe FGF family includes secreted FGFs—the FGF1, FGF4, FGF7, FGF8, FGF9 and FGF15/19 subfamilies—and intracellular FGFs—the FGF11 subfamily [26,27] (figure 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs—also known as FGF homologous factors (FHFs) (figure 2a)—serve as cofactors for members of the voltage-gated sodium channel family, mitogen-activated protein kinase 8-interacting protein 2 (MAPK8IP2), β-tubulin and NF-κB essential modulator (NEMO) [40–43].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are five FGFR genes, and FGFR1–3 can be alternatively spliced into variants of immunoglobulin-like domain III, referred to as ‘b’ and ‘c’, which are essential for ligand-binding specificity and are mainly expressed in epithelial and mesenchymal cells, respectively [4,45–47] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR1c and 3c interact with FGF2, members of the FGF4, 8 and 9 subfamilies, and with the endocrine FGFs (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR2c can bind the same FGFs as the other two mesenchymal isoforms of FGFR with the exception of the endocrine FGFs FGF21 and FGF23 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The epithelial isoforms of FGFR1 and 2, FGFR1b and 2b, are preferentially activated by the FGF7 subfamily—with FGF7 specific for FGFR2b, whereas FGFR3b interacts with the FGF8 and 9 subfamilies [49,50] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The endocrine FGF15/19 subfamily has higher affinity for the mesenchymal isoforms of FGFR1–3 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR4 is activated not only upon FGF2, 4, 6, 8, 17 and 18 binding but also by the endocrine ligands FGF15/19 and FGF23 [51] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regulatory mechanisms may occur at different levels: in the extracellular environment, at the plasma membrane, during internalization and sorting or translocation to the nucleus, and through feedback signalling mechanisms (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Other cell surface molecules, like anosmin-1, Similar Expression to Fgf (SEF), and the adhesion molecules N-cadherin or Neuronal Cell Adhesion Molecule (NCAM), can modulate FGFR signalling in different cell contexts and organs [63–67], thus enlarging the variety of extracellular modulator of FGFR signalling [10] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Similarities and differences in signalling of the four FGFRs could be also determined by sub-cellular localization (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, nuclear translocation of FGFR1 and FGFR2 has been shown to specify the behaviour of cancer cells by regulating signalling and transcription [73,74], thus adding a further layer of complexity in the regulation of FGFR activity (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SPROUTY interacts with GRB2 to regulate the activation of MAPK and PI3K–AKT downstream from FGFR phosphorylation [77,78] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Finally, the E3 ubiquitin ligase CBL induces the ubiquitylation of FGFR after receptor internalization and regulates the sorting of FGFR into the degradative pathway which results in signalling termination [81] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in Fgf10 knock-out mice this defect is less pronounced, owing to the redundant expression of another FGFR2b-specific ligand, FGF7 [31] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the mammary gland epithelium fails to ramify in the Fgf10 knock-out mice, where an underdeveloped mammary fat pad has also been observed [31], suggesting a role for FGF10 in the formation of adipocytes via FGFR1b signalling [86] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the several FGFs produced by the mammary gland stroma, including FGF2, FGF7, FGF9 and FGF10, regulate epithelial morphogenesis through FGFR1 and FGFR2 activation [88] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This ductal/ lobular cellular bilayer is encapsulated by the diverse cell types (immune and non-immune) of the tumour microenvironment (TME) and stromal tissue (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "10%)), using laboratory-based immunohistochemistry and/or in situ hybridization assays based on differential expression of oestrogen, progesterone and the HER2 receptor (ER, PR and HER2) (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Activation of FGFRs in breast cancer is attributed to receptor gene amplification and mutations, gene fusions resulting from translocations and amplification, and more rarely alternative splicing [3] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Schematic of breast cancer extracellular environment (from figure 1) and breast cancer epithelial cells (from figures 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The black lines on the ‘FGF’ text indicate the lack of available information on the role of those specific FGFs in breast cancer.Numerous FGF genes are amplified or show deregulated levels of transcripts and proteins and are often overexpressed in the extracellular matrix or in the stroma, all mechanisms contributing to the amplification of FGFR signalling or the inhibition of its regulatory mechanisms [113] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We will highlight their known genetic alterations, and discuss how dysregulated signalling pathways and cellular localization, and interactions with the microenvironment globally affect the behaviour of breast cancer cells (figure 4).5.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF1 subfamily: FGF1, FGF2\nThe FGF1 subfamily is composed of FGF1 (also known as acidic FGF) and of FGF2 (also known as basic FGF) (figure 2a,b), which have minor roles during development, but are crucial for tissue repair after injury in the adult and in angiogenesis [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF2 regulates tumour growth and migration in vitro and in xenograft models [125], not only by activating FGFR1 signalling [126], but also through oestrogen receptor (ER) signalling [127] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Both FGF1 and FGF2 play a crucial role in breast cancer angiogenesis [129,130] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF4 subfamily: FGF4, FGF5, FGF6\nThe FGF4 subfamily is composed of FGF4, which is crucial for early development in mice, FGF5 and FGF6, whose deletion in mice does not have a known phenotype [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF7 subfamily: FGF3, FGF7, FGF10, FGF22\nMembers of the FGF7 subfamily are FGF3, FGF7, FGF10 and FGF22 (figure 2a,b), of which FGF10 is known to be involved in the formation of mammary gland during development [2] (see §4.2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, anti-FGF3/FGFR2b therapies may benefit patients with HER2-positive breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In terms of signalling pathway activation, FGF7 binding to its receptor FGFR2b (figure 2b) also activates ERK1/2, which in turn promotes FGF7-dependent migration of ER-positive breast cancer cells [150].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF10 is also expressed exclusively by the stromal fibroblasts of normal and breast cancer tissue and has been reported to be an oncogene in mammary tumour virus mouse models and in a subset of breast carcinomas showing high expression of the protein [153,154] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This is due to the paracrine action of FGF10 on its receptor, the FGFR2b isoform, which is highly abundant on the mammary gland [157] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF8 subfamily: FGF8, FGF17, FGF18\nThe FGF8 subfamily is composed of FGF8, FGF17 and FGF18 (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF9 subfamily: FGF9, FGF16, FGF20\nMembers of the FGF9 subfamily (FGF9, FGF16, FGF20 (figure 2a,b)) regulate development at multiple levels in lungs, male germ cells, skeleton, small intestine and cardiomyocytes [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF9 is highly expressed in breast cancer compared with normal tissue, although its expression is not as high as the expression of other FGFs like FGF1 [134] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The endocrine FGFs: FGF15/19, FGF21, FGF23\nThe endocrine FGFs have several roles both during development and in the homeostasis of adult tissues [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Given the role of FGF21 in metabolism and the important relationship between metabolism and breast cancer [172], it has been suggested that monitoring the serum levels of FGF21 during anti-breast cancer therapies could be valuable, although more data are necessary to shed light on the role of FGF21 in breast cancer [173] (figure 4).5.3.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs: FGF11, FGF12, FGF13, FGF14\nMice knocked-out for intracellular FGFs (figure 2a,b) present various defects in neurons (Fgf13 and Fgf14 knock-out) and altered voltage-gated sodium channel physiology (Fgf14 knock-out) [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the same lines, the expression of a long non-coding RNA, FGF14 antisense RNA 2, was downregulated in breast compared with normal tissue, and this correlates with larger tumour size and more lymph node metastasis [175] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In vivo, resistance to CDK4/6 and to anti-HER2 treatment inhibitors can be reversed by combination with anti-FGFR drugs, such as lucitanib or erdafitinib [136,184]; this indicates the importance of targeting different pathways in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This may represent one of the mechanisms responsible for acquired resistance to the anti-HER2 drug lapatinib [187], and this finding suggests that inhibiting both FGFR1 and HER2 signalling might be beneficial for patients (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR1 signalling associated with ER in the nuclei of breast cancer cells regulates the transcription of ER-dependent genes, contributing to mechanisms of resistance in ER-positive samples [191] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The crosstalk between FGFR1 and other signalling pathways in responding to changes of the environment is also exemplified by data showing that the inhibition of both FGFR1 and VEGFR is more efficient in reducing tumour angiogenesis than either treatment alone [197,198] (figure 4).6.2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, very recently it has been reported that FGFR2 can be expressed also in ER/PR-positive tumours where, surprisingly, low FGFR2 expression correlates with poor prognosis [201] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the signalling cascades activated by FGF10 downstream of FGFR2b were reported to counteract ER-dependent signalling [156] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR2 signalling promotes HER2 shedding through the metalloprotease ADAM10 and enhances HER2 signalling, HER2-dependent proliferation and tumour progression in mouse xenografts [216] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the authors showed that FGF5 secreted by cancer-associated fibroblasts (CAF) in the microenvironment might be responsible for the high activation of FGFR2 on the neighbouring epithelial cells [137], confirming the potential signalling switch between HER2 and FGFR2 in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF7, another specific ligand for FGFR2b (figure 2a,b) has been shown to trigger phosphorylation of progesterone receptor at Ser294 and its degradation via the FGFR2–RSK2 signalling axis [151].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A potential mechanism underlying this effect is FGFR4-mediated regulation of membrane ruffling in response to both FGF1 and 2 [122] (figure 2a,b), which might increase AKT signalling.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The role of FGFR4 in liver metabolism may offer an alternative explanation to link AKT signalling and survival depending on FGFR4 signalling [222] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Given the variety of phenotypes of mice knocked-out for Fgfr isoforms [4], the differential expression and role of the ‘b’ and ‘c’ variants in tissue [61], and the possibility of trans-phosphorylation between different FGFRs [245], it is worth speculating that the landscape of dysregulated FGFR signalling is much more complex than the one presented here (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Among these RTKs, there are epidermal growth factor receptors (EGFRs), vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), insulin-like growth factor receptors (IGFRs) and FGFRs [6] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Upon ligand stimulation, RTKs activate several pathways, including mitogen-activated protein kinase (MAPK), Janus kinase (JAK)/signal transducer and activator of transcription (STAT), phospholipase C gamma (PLCγ) and phosphoinositide 3-kinase (PI3–K) [7] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RTK signalling regulates the response of cancer cells to perturbation of the extracellular environment, composed of fibroblasts, adipocytes, immune cells, and proteins of the extracellular matrix and of the extended vasculature [8] (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The different subfamilies are based on the biochemical properties, sequence similarities and evolutionary relationships of their members (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Firstly, Y653, in the activation loop, is phosphorylated, followed by the phosphorylation of Y583, Y463, Y654, Y677, Y766 and Y585, whereas Y730 is weakly phosphorylated [11–13] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FRS2α, which is constitutively associated with the receptor, is phosphorylated upon ligand binding, and recruits adaptor proteins, like GRB2, which in turn recruits SOS followed by members of the MAPK family, and GAB1, which then activates the PI3K–AKT signalling axis [15] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "By contrast, AKT induces the activation of the mTOR complex 1 [22] and the phosphorylation of the FOXO1 transcription factor [23] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Following recruitment to activated FGFR the enzyme PLCγ induces calcium ion release, resulting in the activation of downstream kinases like PKC [24] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR also activates STAT1, 3 and 5, which regulate gene expression in the nucleus [25] (figure 2c).3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFs, FGFRs and cofactors\nThe FGF family includes secreted FGFs—the FGF1, FGF4, FGF7, FGF8, FGF9 and FGF15/19 subfamilies—and intracellular FGFs—the FGF11 subfamily [26,27] (figure 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs—also known as FGF homologous factors (FHFs) (figure 2a)—serve as cofactors for members of the voltage-gated sodium channel family, mitogen-activated protein kinase 8-interacting protein 2 (MAPK8IP2), β-tubulin and NF-κB essential modulator (NEMO) [40–43].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are five FGFR genes, and FGFR1–3 can be alternatively spliced into variants of immunoglobulin-like domain III, referred to as ‘b’ and ‘c’, which are essential for ligand-binding specificity and are mainly expressed in epithelial and mesenchymal cells, respectively [4,45–47] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR1c and 3c interact with FGF2, members of the FGF4, 8 and 9 subfamilies, and with the endocrine FGFs (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR2c can bind the same FGFs as the other two mesenchymal isoforms of FGFR with the exception of the endocrine FGFs FGF21 and FGF23 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The epithelial isoforms of FGFR1 and 2, FGFR1b and 2b, are preferentially activated by the FGF7 subfamily—with FGF7 specific for FGFR2b, whereas FGFR3b interacts with the FGF8 and 9 subfamilies [49,50] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The endocrine FGF15/19 subfamily has higher affinity for the mesenchymal isoforms of FGFR1–3 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR4 is activated not only upon FGF2, 4, 6, 8, 17 and 18 binding but also by the endocrine ligands FGF15/19 and FGF23 [51] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regulatory mechanisms may occur at different levels: in the extracellular environment, at the plasma membrane, during internalization and sorting or translocation to the nucleus, and through feedback signalling mechanisms (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Other cell surface molecules, like anosmin-1, Similar Expression to Fgf (SEF), and the adhesion molecules N-cadherin or Neuronal Cell Adhesion Molecule (NCAM), can modulate FGFR signalling in different cell contexts and organs [63–67], thus enlarging the variety of extracellular modulator of FGFR signalling [10] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Similarities and differences in signalling of the four FGFRs could be also determined by sub-cellular localization (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, nuclear translocation of FGFR1 and FGFR2 has been shown to specify the behaviour of cancer cells by regulating signalling and transcription [73,74], thus adding a further layer of complexity in the regulation of FGFR activity (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SPROUTY interacts with GRB2 to regulate the activation of MAPK and PI3K–AKT downstream from FGFR phosphorylation [77,78] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Finally, the E3 ubiquitin ligase CBL induces the ubiquitylation of FGFR after receptor internalization and regulates the sorting of FGFR into the degradative pathway which results in signalling termination [81] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in Fgf10 knock-out mice this defect is less pronounced, owing to the redundant expression of another FGFR2b-specific ligand, FGF7 [31] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the mammary gland epithelium fails to ramify in the Fgf10 knock-out mice, where an underdeveloped mammary fat pad has also been observed [31], suggesting a role for FGF10 in the formation of adipocytes via FGFR1b signalling [86] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the several FGFs produced by the mammary gland stroma, including FGF2, FGF7, FGF9 and FGF10, regulate epithelial morphogenesis through FGFR1 and FGFR2 activation [88] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This ductal/ lobular cellular bilayer is encapsulated by the diverse cell types (immune and non-immune) of the tumour microenvironment (TME) and stromal tissue (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "10%)), using laboratory-based immunohistochemistry and/or in situ hybridization assays based on differential expression of oestrogen, progesterone and the HER2 receptor (ER, PR and HER2) (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Activation of FGFRs in breast cancer is attributed to receptor gene amplification and mutations, gene fusions resulting from translocations and amplification, and more rarely alternative splicing [3] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Schematic of breast cancer extracellular environment (from figure 1) and breast cancer epithelial cells (from figures 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The black lines on the ‘FGF’ text indicate the lack of available information on the role of those specific FGFs in breast cancer.Numerous FGF genes are amplified or show deregulated levels of transcripts and proteins and are often overexpressed in the extracellular matrix or in the stroma, all mechanisms contributing to the amplification of FGFR signalling or the inhibition of its regulatory mechanisms [113] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We will highlight their known genetic alterations, and discuss how dysregulated signalling pathways and cellular localization, and interactions with the microenvironment globally affect the behaviour of breast cancer cells (figure 4).5.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF1 subfamily: FGF1, FGF2\nThe FGF1 subfamily is composed of FGF1 (also known as acidic FGF) and of FGF2 (also known as basic FGF) (figure 2a,b), which have minor roles during development, but are crucial for tissue repair after injury in the adult and in angiogenesis [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF2 regulates tumour growth and migration in vitro and in xenograft models [125], not only by activating FGFR1 signalling [126], but also through oestrogen receptor (ER) signalling [127] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Both FGF1 and FGF2 play a crucial role in breast cancer angiogenesis [129,130] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF4 subfamily: FGF4, FGF5, FGF6\nThe FGF4 subfamily is composed of FGF4, which is crucial for early development in mice, FGF5 and FGF6, whose deletion in mice does not have a known phenotype [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF7 subfamily: FGF3, FGF7, FGF10, FGF22\nMembers of the FGF7 subfamily are FGF3, FGF7, FGF10 and FGF22 (figure 2a,b), of which FGF10 is known to be involved in the formation of mammary gland during development [2] (see §4.2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, anti-FGF3/FGFR2b therapies may benefit patients with HER2-positive breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In terms of signalling pathway activation, FGF7 binding to its receptor FGFR2b (figure 2b) also activates ERK1/2, which in turn promotes FGF7-dependent migration of ER-positive breast cancer cells [150].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF10 is also expressed exclusively by the stromal fibroblasts of normal and breast cancer tissue and has been reported to be an oncogene in mammary tumour virus mouse models and in a subset of breast carcinomas showing high expression of the protein [153,154] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This is due to the paracrine action of FGF10 on its receptor, the FGFR2b isoform, which is highly abundant on the mammary gland [157] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF8 subfamily: FGF8, FGF17, FGF18\nThe FGF8 subfamily is composed of FGF8, FGF17 and FGF18 (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF9 subfamily: FGF9, FGF16, FGF20\nMembers of the FGF9 subfamily (FGF9, FGF16, FGF20 (figure 2a,b)) regulate development at multiple levels in lungs, male germ cells, skeleton, small intestine and cardiomyocytes [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF9 is highly expressed in breast cancer compared with normal tissue, although its expression is not as high as the expression of other FGFs like FGF1 [134] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The endocrine FGFs: FGF15/19, FGF21, FGF23\nThe endocrine FGFs have several roles both during development and in the homeostasis of adult tissues [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Given the role of FGF21 in metabolism and the important relationship between metabolism and breast cancer [172], it has been suggested that monitoring the serum levels of FGF21 during anti-breast cancer therapies could be valuable, although more data are necessary to shed light on the role of FGF21 in breast cancer [173] (figure 4).5.3.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs: FGF11, FGF12, FGF13, FGF14\nMice knocked-out for intracellular FGFs (figure 2a,b) present various defects in neurons (Fgf13 and Fgf14 knock-out) and altered voltage-gated sodium channel physiology (Fgf14 knock-out) [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the same lines, the expression of a long non-coding RNA, FGF14 antisense RNA 2, was downregulated in breast compared with normal tissue, and this correlates with larger tumour size and more lymph node metastasis [175] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In vivo, resistance to CDK4/6 and to anti-HER2 treatment inhibitors can be reversed by combination with anti-FGFR drugs, such as lucitanib or erdafitinib [136,184]; this indicates the importance of targeting different pathways in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This may represent one of the mechanisms responsible for acquired resistance to the anti-HER2 drug lapatinib [187], and this finding suggests that inhibiting both FGFR1 and HER2 signalling might be beneficial for patients (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR1 signalling associated with ER in the nuclei of breast cancer cells regulates the transcription of ER-dependent genes, contributing to mechanisms of resistance in ER-positive samples [191] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The crosstalk between FGFR1 and other signalling pathways in responding to changes of the environment is also exemplified by data showing that the inhibition of both FGFR1 and VEGFR is more efficient in reducing tumour angiogenesis than either treatment alone [197,198] (figure 4).6.2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, very recently it has been reported that FGFR2 can be expressed also in ER/PR-positive tumours where, surprisingly, low FGFR2 expression correlates with poor prognosis [201] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the signalling cascades activated by FGF10 downstream of FGFR2b were reported to counteract ER-dependent signalling [156] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR2 signalling promotes HER2 shedding through the metalloprotease ADAM10 and enhances HER2 signalling, HER2-dependent proliferation and tumour progression in mouse xenografts [216] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the authors showed that FGF5 secreted by cancer-associated fibroblasts (CAF) in the microenvironment might be responsible for the high activation of FGFR2 on the neighbouring epithelial cells [137], confirming the potential signalling switch between HER2 and FGFR2 in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF7, another specific ligand for FGFR2b (figure 2a,b) has been shown to trigger phosphorylation of progesterone receptor at Ser294 and its degradation via the FGFR2–RSK2 signalling axis [151].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A potential mechanism underlying this effect is FGFR4-mediated regulation of membrane ruffling in response to both FGF1 and 2 [122] (figure 2a,b), which might increase AKT signalling.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The role of FGFR4 in liver metabolism may offer an alternative explanation to link AKT signalling and survival depending on FGFR4 signalling [222] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Given the variety of phenotypes of mice knocked-out for Fgfr isoforms [4], the differential expression and role of the ‘b’ and ‘c’ variants in tissue [61], and the possibility of trans-phosphorylation between different FGFRs [245], it is worth speculating that the landscape of dysregulated FGFR signalling is much more complex than the one presented here (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Among these RTKs, there are epidermal growth factor receptors (EGFRs), vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), insulin-like growth factor receptors (IGFRs) and FGFRs [6] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Upon ligand stimulation, RTKs activate several pathways, including mitogen-activated protein kinase (MAPK), Janus kinase (JAK)/signal transducer and activator of transcription (STAT), phospholipase C gamma (PLCγ) and phosphoinositide 3-kinase (PI3–K) [7] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RTK signalling regulates the response of cancer cells to perturbation of the extracellular environment, composed of fibroblasts, adipocytes, immune cells, and proteins of the extracellular matrix and of the extended vasculature [8] (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The different subfamilies are based on the biochemical properties, sequence similarities and evolutionary relationships of their members (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Firstly, Y653, in the activation loop, is phosphorylated, followed by the phosphorylation of Y583, Y463, Y654, Y677, Y766 and Y585, whereas Y730 is weakly phosphorylated [11–13] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FRS2α, which is constitutively associated with the receptor, is phosphorylated upon ligand binding, and recruits adaptor proteins, like GRB2, which in turn recruits SOS followed by members of the MAPK family, and GAB1, which then activates the PI3K–AKT signalling axis [15] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "By contrast, AKT induces the activation of the mTOR complex 1 [22] and the phosphorylation of the FOXO1 transcription factor [23] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Following recruitment to activated FGFR the enzyme PLCγ induces calcium ion release, resulting in the activation of downstream kinases like PKC [24] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR also activates STAT1, 3 and 5, which regulate gene expression in the nucleus [25] (figure 2c).3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFs, FGFRs and cofactors\nThe FGF family includes secreted FGFs—the FGF1, FGF4, FGF7, FGF8, FGF9 and FGF15/19 subfamilies—and intracellular FGFs—the FGF11 subfamily [26,27] (figure 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs—also known as FGF homologous factors (FHFs) (figure 2a)—serve as cofactors for members of the voltage-gated sodium channel family, mitogen-activated protein kinase 8-interacting protein 2 (MAPK8IP2), β-tubulin and NF-κB essential modulator (NEMO) [40–43].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are five FGFR genes, and FGFR1–3 can be alternatively spliced into variants of immunoglobulin-like domain III, referred to as ‘b’ and ‘c’, which are essential for ligand-binding specificity and are mainly expressed in epithelial and mesenchymal cells, respectively [4,45–47] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR1c and 3c interact with FGF2, members of the FGF4, 8 and 9 subfamilies, and with the endocrine FGFs (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR2c can bind the same FGFs as the other two mesenchymal isoforms of FGFR with the exception of the endocrine FGFs FGF21 and FGF23 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The epithelial isoforms of FGFR1 and 2, FGFR1b and 2b, are preferentially activated by the FGF7 subfamily—with FGF7 specific for FGFR2b, whereas FGFR3b interacts with the FGF8 and 9 subfamilies [49,50] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The endocrine FGF15/19 subfamily has higher affinity for the mesenchymal isoforms of FGFR1–3 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR4 is activated not only upon FGF2, 4, 6, 8, 17 and 18 binding but also by the endocrine ligands FGF15/19 and FGF23 [51] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regulatory mechanisms may occur at different levels: in the extracellular environment, at the plasma membrane, during internalization and sorting or translocation to the nucleus, and through feedback signalling mechanisms (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Other cell surface molecules, like anosmin-1, Similar Expression to Fgf (SEF), and the adhesion molecules N-cadherin or Neuronal Cell Adhesion Molecule (NCAM), can modulate FGFR signalling in different cell contexts and organs [63–67], thus enlarging the variety of extracellular modulator of FGFR signalling [10] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Similarities and differences in signalling of the four FGFRs could be also determined by sub-cellular localization (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, nuclear translocation of FGFR1 and FGFR2 has been shown to specify the behaviour of cancer cells by regulating signalling and transcription [73,74], thus adding a further layer of complexity in the regulation of FGFR activity (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SPROUTY interacts with GRB2 to regulate the activation of MAPK and PI3K–AKT downstream from FGFR phosphorylation [77,78] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Finally, the E3 ubiquitin ligase CBL induces the ubiquitylation of FGFR after receptor internalization and regulates the sorting of FGFR into the degradative pathway which results in signalling termination [81] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in Fgf10 knock-out mice this defect is less pronounced, owing to the redundant expression of another FGFR2b-specific ligand, FGF7 [31] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the mammary gland epithelium fails to ramify in the Fgf10 knock-out mice, where an underdeveloped mammary fat pad has also been observed [31], suggesting a role for FGF10 in the formation of adipocytes via FGFR1b signalling [86] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the several FGFs produced by the mammary gland stroma, including FGF2, FGF7, FGF9 and FGF10, regulate epithelial morphogenesis through FGFR1 and FGFR2 activation [88] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This ductal/ lobular cellular bilayer is encapsulated by the diverse cell types (immune and non-immune) of the tumour microenvironment (TME) and stromal tissue (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "10%)), using laboratory-based immunohistochemistry and/or in situ hybridization assays based on differential expression of oestrogen, progesterone and the HER2 receptor (ER, PR and HER2) (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Activation of FGFRs in breast cancer is attributed to receptor gene amplification and mutations, gene fusions resulting from translocations and amplification, and more rarely alternative splicing [3] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Schematic of breast cancer extracellular environment (from figure 1) and breast cancer epithelial cells (from figures 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The black lines on the ‘FGF’ text indicate the lack of available information on the role of those specific FGFs in breast cancer.Numerous FGF genes are amplified or show deregulated levels of transcripts and proteins and are often overexpressed in the extracellular matrix or in the stroma, all mechanisms contributing to the amplification of FGFR signalling or the inhibition of its regulatory mechanisms [113] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We will highlight their known genetic alterations, and discuss how dysregulated signalling pathways and cellular localization, and interactions with the microenvironment globally affect the behaviour of breast cancer cells (figure 4).5.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF1 subfamily: FGF1, FGF2\nThe FGF1 subfamily is composed of FGF1 (also known as acidic FGF) and of FGF2 (also known as basic FGF) (figure 2a,b), which have minor roles during development, but are crucial for tissue repair after injury in the adult and in angiogenesis [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF2 regulates tumour growth and migration in vitro and in xenograft models [125], not only by activating FGFR1 signalling [126], but also through oestrogen receptor (ER) signalling [127] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Both FGF1 and FGF2 play a crucial role in breast cancer angiogenesis [129,130] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF4 subfamily: FGF4, FGF5, FGF6\nThe FGF4 subfamily is composed of FGF4, which is crucial for early development in mice, FGF5 and FGF6, whose deletion in mice does not have a known phenotype [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF7 subfamily: FGF3, FGF7, FGF10, FGF22\nMembers of the FGF7 subfamily are FGF3, FGF7, FGF10 and FGF22 (figure 2a,b), of which FGF10 is known to be involved in the formation of mammary gland during development [2] (see §4.2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, anti-FGF3/FGFR2b therapies may benefit patients with HER2-positive breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In terms of signalling pathway activation, FGF7 binding to its receptor FGFR2b (figure 2b) also activates ERK1/2, which in turn promotes FGF7-dependent migration of ER-positive breast cancer cells [150].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF10 is also expressed exclusively by the stromal fibroblasts of normal and breast cancer tissue and has been reported to be an oncogene in mammary tumour virus mouse models and in a subset of breast carcinomas showing high expression of the protein [153,154] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This is due to the paracrine action of FGF10 on its receptor, the FGFR2b isoform, which is highly abundant on the mammary gland [157] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF8 subfamily: FGF8, FGF17, FGF18\nThe FGF8 subfamily is composed of FGF8, FGF17 and FGF18 (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF9 subfamily: FGF9, FGF16, FGF20\nMembers of the FGF9 subfamily (FGF9, FGF16, FGF20 (figure 2a,b)) regulate development at multiple levels in lungs, male germ cells, skeleton, small intestine and cardiomyocytes [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF9 is highly expressed in breast cancer compared with normal tissue, although its expression is not as high as the expression of other FGFs like FGF1 [134] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The endocrine FGFs: FGF15/19, FGF21, FGF23\nThe endocrine FGFs have several roles both during development and in the homeostasis of adult tissues [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Given the role of FGF21 in metabolism and the important relationship between metabolism and breast cancer [172], it has been suggested that monitoring the serum levels of FGF21 during anti-breast cancer therapies could be valuable, although more data are necessary to shed light on the role of FGF21 in breast cancer [173] (figure 4).5.3.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs: FGF11, FGF12, FGF13, FGF14\nMice knocked-out for intracellular FGFs (figure 2a,b) present various defects in neurons (Fgf13 and Fgf14 knock-out) and altered voltage-gated sodium channel physiology (Fgf14 knock-out) [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the same lines, the expression of a long non-coding RNA, FGF14 antisense RNA 2, was downregulated in breast compared with normal tissue, and this correlates with larger tumour size and more lymph node metastasis [175] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In vivo, resistance to CDK4/6 and to anti-HER2 treatment inhibitors can be reversed by combination with anti-FGFR drugs, such as lucitanib or erdafitinib [136,184]; this indicates the importance of targeting different pathways in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This may represent one of the mechanisms responsible for acquired resistance to the anti-HER2 drug lapatinib [187], and this finding suggests that inhibiting both FGFR1 and HER2 signalling might be beneficial for patients (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR1 signalling associated with ER in the nuclei of breast cancer cells regulates the transcription of ER-dependent genes, contributing to mechanisms of resistance in ER-positive samples [191] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The crosstalk between FGFR1 and other signalling pathways in responding to changes of the environment is also exemplified by data showing that the inhibition of both FGFR1 and VEGFR is more efficient in reducing tumour angiogenesis than either treatment alone [197,198] (figure 4).6.2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, very recently it has been reported that FGFR2 can be expressed also in ER/PR-positive tumours where, surprisingly, low FGFR2 expression correlates with poor prognosis [201] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the signalling cascades activated by FGF10 downstream of FGFR2b were reported to counteract ER-dependent signalling [156] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR2 signalling promotes HER2 shedding through the metalloprotease ADAM10 and enhances HER2 signalling, HER2-dependent proliferation and tumour progression in mouse xenografts [216] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the authors showed that FGF5 secreted by cancer-associated fibroblasts (CAF) in the microenvironment might be responsible for the high activation of FGFR2 on the neighbouring epithelial cells [137], confirming the potential signalling switch between HER2 and FGFR2 in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF7, another specific ligand for FGFR2b (figure 2a,b) has been shown to trigger phosphorylation of progesterone receptor at Ser294 and its degradation via the FGFR2–RSK2 signalling axis [151].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A potential mechanism underlying this effect is FGFR4-mediated regulation of membrane ruffling in response to both FGF1 and 2 [122] (figure 2a,b), which might increase AKT signalling.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The role of FGFR4 in liver metabolism may offer an alternative explanation to link AKT signalling and survival depending on FGFR4 signalling [222] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Given the variety of phenotypes of mice knocked-out for Fgfr isoforms [4], the differential expression and role of the ‘b’ and ‘c’ variants in tissue [61], and the possibility of trans-phosphorylation between different FGFRs [245], it is worth speculating that the landscape of dysregulated FGFR signalling is much more complex than the one presented here (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Among these RTKs, there are epidermal growth factor receptors (EGFRs), vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), insulin-like growth factor receptors (IGFRs) and FGFRs [6] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Upon ligand stimulation, RTKs activate several pathways, including mitogen-activated protein kinase (MAPK), Janus kinase (JAK)/signal transducer and activator of transcription (STAT), phospholipase C gamma (PLCγ) and phosphoinositide 3-kinase (PI3–K) [7] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RTK signalling regulates the response of cancer cells to perturbation of the extracellular environment, composed of fibroblasts, adipocytes, immune cells, and proteins of the extracellular matrix and of the extended vasculature [8] (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The different subfamilies are based on the biochemical properties, sequence similarities and evolutionary relationships of their members (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Firstly, Y653, in the activation loop, is phosphorylated, followed by the phosphorylation of Y583, Y463, Y654, Y677, Y766 and Y585, whereas Y730 is weakly phosphorylated [11–13] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FRS2α, which is constitutively associated with the receptor, is phosphorylated upon ligand binding, and recruits adaptor proteins, like GRB2, which in turn recruits SOS followed by members of the MAPK family, and GAB1, which then activates the PI3K–AKT signalling axis [15] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "By contrast, AKT induces the activation of the mTOR complex 1 [22] and the phosphorylation of the FOXO1 transcription factor [23] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Following recruitment to activated FGFR the enzyme PLCγ induces calcium ion release, resulting in the activation of downstream kinases like PKC [24] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR also activates STAT1, 3 and 5, which regulate gene expression in the nucleus [25] (figure 2c).3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFs, FGFRs and cofactors\nThe FGF family includes secreted FGFs—the FGF1, FGF4, FGF7, FGF8, FGF9 and FGF15/19 subfamilies—and intracellular FGFs—the FGF11 subfamily [26,27] (figure 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs—also known as FGF homologous factors (FHFs) (figure 2a)—serve as cofactors for members of the voltage-gated sodium channel family, mitogen-activated protein kinase 8-interacting protein 2 (MAPK8IP2), β-tubulin and NF-κB essential modulator (NEMO) [40–43].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are five FGFR genes, and FGFR1–3 can be alternatively spliced into variants of immunoglobulin-like domain III, referred to as ‘b’ and ‘c’, which are essential for ligand-binding specificity and are mainly expressed in epithelial and mesenchymal cells, respectively [4,45–47] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR1c and 3c interact with FGF2, members of the FGF4, 8 and 9 subfamilies, and with the endocrine FGFs (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR2c can bind the same FGFs as the other two mesenchymal isoforms of FGFR with the exception of the endocrine FGFs FGF21 and FGF23 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The epithelial isoforms of FGFR1 and 2, FGFR1b and 2b, are preferentially activated by the FGF7 subfamily—with FGF7 specific for FGFR2b, whereas FGFR3b interacts with the FGF8 and 9 subfamilies [49,50] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The endocrine FGF15/19 subfamily has higher affinity for the mesenchymal isoforms of FGFR1–3 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR4 is activated not only upon FGF2, 4, 6, 8, 17 and 18 binding but also by the endocrine ligands FGF15/19 and FGF23 [51] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regulatory mechanisms may occur at different levels: in the extracellular environment, at the plasma membrane, during internalization and sorting or translocation to the nucleus, and through feedback signalling mechanisms (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Other cell surface molecules, like anosmin-1, Similar Expression to Fgf (SEF), and the adhesion molecules N-cadherin or Neuronal Cell Adhesion Molecule (NCAM), can modulate FGFR signalling in different cell contexts and organs [63–67], thus enlarging the variety of extracellular modulator of FGFR signalling [10] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Similarities and differences in signalling of the four FGFRs could be also determined by sub-cellular localization (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, nuclear translocation of FGFR1 and FGFR2 has been shown to specify the behaviour of cancer cells by regulating signalling and transcription [73,74], thus adding a further layer of complexity in the regulation of FGFR activity (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SPROUTY interacts with GRB2 to regulate the activation of MAPK and PI3K–AKT downstream from FGFR phosphorylation [77,78] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Finally, the E3 ubiquitin ligase CBL induces the ubiquitylation of FGFR after receptor internalization and regulates the sorting of FGFR into the degradative pathway which results in signalling termination [81] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in Fgf10 knock-out mice this defect is less pronounced, owing to the redundant expression of another FGFR2b-specific ligand, FGF7 [31] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the mammary gland epithelium fails to ramify in the Fgf10 knock-out mice, where an underdeveloped mammary fat pad has also been observed [31], suggesting a role for FGF10 in the formation of adipocytes via FGFR1b signalling [86] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the several FGFs produced by the mammary gland stroma, including FGF2, FGF7, FGF9 and FGF10, regulate epithelial morphogenesis through FGFR1 and FGFR2 activation [88] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This ductal/ lobular cellular bilayer is encapsulated by the diverse cell types (immune and non-immune) of the tumour microenvironment (TME) and stromal tissue (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "10%)), using laboratory-based immunohistochemistry and/or in situ hybridization assays based on differential expression of oestrogen, progesterone and the HER2 receptor (ER, PR and HER2) (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Activation of FGFRs in breast cancer is attributed to receptor gene amplification and mutations, gene fusions resulting from translocations and amplification, and more rarely alternative splicing [3] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Schematic of breast cancer extracellular environment (from figure 1) and breast cancer epithelial cells (from figures 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The black lines on the ‘FGF’ text indicate the lack of available information on the role of those specific FGFs in breast cancer.Numerous FGF genes are amplified or show deregulated levels of transcripts and proteins and are often overexpressed in the extracellular matrix or in the stroma, all mechanisms contributing to the amplification of FGFR signalling or the inhibition of its regulatory mechanisms [113] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We will highlight their known genetic alterations, and discuss how dysregulated signalling pathways and cellular localization, and interactions with the microenvironment globally affect the behaviour of breast cancer cells (figure 4).5.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF1 subfamily: FGF1, FGF2\nThe FGF1 subfamily is composed of FGF1 (also known as acidic FGF) and of FGF2 (also known as basic FGF) (figure 2a,b), which have minor roles during development, but are crucial for tissue repair after injury in the adult and in angiogenesis [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF2 regulates tumour growth and migration in vitro and in xenograft models [125], not only by activating FGFR1 signalling [126], but also through oestrogen receptor (ER) signalling [127] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Both FGF1 and FGF2 play a crucial role in breast cancer angiogenesis [129,130] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF4 subfamily: FGF4, FGF5, FGF6\nThe FGF4 subfamily is composed of FGF4, which is crucial for early development in mice, FGF5 and FGF6, whose deletion in mice does not have a known phenotype [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF7 subfamily: FGF3, FGF7, FGF10, FGF22\nMembers of the FGF7 subfamily are FGF3, FGF7, FGF10 and FGF22 (figure 2a,b), of which FGF10 is known to be involved in the formation of mammary gland during development [2] (see §4.2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, anti-FGF3/FGFR2b therapies may benefit patients with HER2-positive breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In terms of signalling pathway activation, FGF7 binding to its receptor FGFR2b (figure 2b) also activates ERK1/2, which in turn promotes FGF7-dependent migration of ER-positive breast cancer cells [150].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF10 is also expressed exclusively by the stromal fibroblasts of normal and breast cancer tissue and has been reported to be an oncogene in mammary tumour virus mouse models and in a subset of breast carcinomas showing high expression of the protein [153,154] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This is due to the paracrine action of FGF10 on its receptor, the FGFR2b isoform, which is highly abundant on the mammary gland [157] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF8 subfamily: FGF8, FGF17, FGF18\nThe FGF8 subfamily is composed of FGF8, FGF17 and FGF18 (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF9 subfamily: FGF9, FGF16, FGF20\nMembers of the FGF9 subfamily (FGF9, FGF16, FGF20 (figure 2a,b)) regulate development at multiple levels in lungs, male germ cells, skeleton, small intestine and cardiomyocytes [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF9 is highly expressed in breast cancer compared with normal tissue, although its expression is not as high as the expression of other FGFs like FGF1 [134] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The endocrine FGFs: FGF15/19, FGF21, FGF23\nThe endocrine FGFs have several roles both during development and in the homeostasis of adult tissues [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Given the role of FGF21 in metabolism and the important relationship between metabolism and breast cancer [172], it has been suggested that monitoring the serum levels of FGF21 during anti-breast cancer therapies could be valuable, although more data are necessary to shed light on the role of FGF21 in breast cancer [173] (figure 4).5.3.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs: FGF11, FGF12, FGF13, FGF14\nMice knocked-out for intracellular FGFs (figure 2a,b) present various defects in neurons (Fgf13 and Fgf14 knock-out) and altered voltage-gated sodium channel physiology (Fgf14 knock-out) [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the same lines, the expression of a long non-coding RNA, FGF14 antisense RNA 2, was downregulated in breast compared with normal tissue, and this correlates with larger tumour size and more lymph node metastasis [175] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In vivo, resistance to CDK4/6 and to anti-HER2 treatment inhibitors can be reversed by combination with anti-FGFR drugs, such as lucitanib or erdafitinib [136,184]; this indicates the importance of targeting different pathways in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This may represent one of the mechanisms responsible for acquired resistance to the anti-HER2 drug lapatinib [187], and this finding suggests that inhibiting both FGFR1 and HER2 signalling might be beneficial for patients (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR1 signalling associated with ER in the nuclei of breast cancer cells regulates the transcription of ER-dependent genes, contributing to mechanisms of resistance in ER-positive samples [191] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The crosstalk between FGFR1 and other signalling pathways in responding to changes of the environment is also exemplified by data showing that the inhibition of both FGFR1 and VEGFR is more efficient in reducing tumour angiogenesis than either treatment alone [197,198] (figure 4).6.2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, very recently it has been reported that FGFR2 can be expressed also in ER/PR-positive tumours where, surprisingly, low FGFR2 expression correlates with poor prognosis [201] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the signalling cascades activated by FGF10 downstream of FGFR2b were reported to counteract ER-dependent signalling [156] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR2 signalling promotes HER2 shedding through the metalloprotease ADAM10 and enhances HER2 signalling, HER2-dependent proliferation and tumour progression in mouse xenografts [216] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the authors showed that FGF5 secreted by cancer-associated fibroblasts (CAF) in the microenvironment might be responsible for the high activation of FGFR2 on the neighbouring epithelial cells [137], confirming the potential signalling switch between HER2 and FGFR2 in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF7, another specific ligand for FGFR2b (figure 2a,b) has been shown to trigger phosphorylation of progesterone receptor at Ser294 and its degradation via the FGFR2–RSK2 signalling axis [151].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A potential mechanism underlying this effect is FGFR4-mediated regulation of membrane ruffling in response to both FGF1 and 2 [122] (figure 2a,b), which might increase AKT signalling.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The role of FGFR4 in liver metabolism may offer an alternative explanation to link AKT signalling and survival depending on FGFR4 signalling [222] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Given the variety of phenotypes of mice knocked-out for Fgfr isoforms [4], the differential expression and role of the ‘b’ and ‘c’ variants in tissue [61], and the possibility of trans-phosphorylation between different FGFRs [245], it is worth speculating that the landscape of dysregulated FGFR signalling is much more complex than the one presented here (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Among these RTKs, there are epidermal growth factor receptors (EGFRs), vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), insulin-like growth factor receptors (IGFRs) and FGFRs [6] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Upon ligand stimulation, RTKs activate several pathways, including mitogen-activated protein kinase (MAPK), Janus kinase (JAK)/signal transducer and activator of transcription (STAT), phospholipase C gamma (PLCγ) and phosphoinositide 3-kinase (PI3–K) [7] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RTK signalling regulates the response of cancer cells to perturbation of the extracellular environment, composed of fibroblasts, adipocytes, immune cells, and proteins of the extracellular matrix and of the extended vasculature [8] (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The different subfamilies are based on the biochemical properties, sequence similarities and evolutionary relationships of their members (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Firstly, Y653, in the activation loop, is phosphorylated, followed by the phosphorylation of Y583, Y463, Y654, Y677, Y766 and Y585, whereas Y730 is weakly phosphorylated [11–13] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FRS2α, which is constitutively associated with the receptor, is phosphorylated upon ligand binding, and recruits adaptor proteins, like GRB2, which in turn recruits SOS followed by members of the MAPK family, and GAB1, which then activates the PI3K–AKT signalling axis [15] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "By contrast, AKT induces the activation of the mTOR complex 1 [22] and the phosphorylation of the FOXO1 transcription factor [23] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Following recruitment to activated FGFR the enzyme PLCγ induces calcium ion release, resulting in the activation of downstream kinases like PKC [24] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR also activates STAT1, 3 and 5, which regulate gene expression in the nucleus [25] (figure 2c).3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFs, FGFRs and cofactors\nThe FGF family includes secreted FGFs—the FGF1, FGF4, FGF7, FGF8, FGF9 and FGF15/19 subfamilies—and intracellular FGFs—the FGF11 subfamily [26,27] (figure 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs—also known as FGF homologous factors (FHFs) (figure 2a)—serve as cofactors for members of the voltage-gated sodium channel family, mitogen-activated protein kinase 8-interacting protein 2 (MAPK8IP2), β-tubulin and NF-κB essential modulator (NEMO) [40–43].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are five FGFR genes, and FGFR1–3 can be alternatively spliced into variants of immunoglobulin-like domain III, referred to as ‘b’ and ‘c’, which are essential for ligand-binding specificity and are mainly expressed in epithelial and mesenchymal cells, respectively [4,45–47] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR1c and 3c interact with FGF2, members of the FGF4, 8 and 9 subfamilies, and with the endocrine FGFs (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR2c can bind the same FGFs as the other two mesenchymal isoforms of FGFR with the exception of the endocrine FGFs FGF21 and FGF23 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The epithelial isoforms of FGFR1 and 2, FGFR1b and 2b, are preferentially activated by the FGF7 subfamily—with FGF7 specific for FGFR2b, whereas FGFR3b interacts with the FGF8 and 9 subfamilies [49,50] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The endocrine FGF15/19 subfamily has higher affinity for the mesenchymal isoforms of FGFR1–3 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR4 is activated not only upon FGF2, 4, 6, 8, 17 and 18 binding but also by the endocrine ligands FGF15/19 and FGF23 [51] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regulatory mechanisms may occur at different levels: in the extracellular environment, at the plasma membrane, during internalization and sorting or translocation to the nucleus, and through feedback signalling mechanisms (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Other cell surface molecules, like anosmin-1, Similar Expression to Fgf (SEF), and the adhesion molecules N-cadherin or Neuronal Cell Adhesion Molecule (NCAM), can modulate FGFR signalling in different cell contexts and organs [63–67], thus enlarging the variety of extracellular modulator of FGFR signalling [10] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Similarities and differences in signalling of the four FGFRs could be also determined by sub-cellular localization (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, nuclear translocation of FGFR1 and FGFR2 has been shown to specify the behaviour of cancer cells by regulating signalling and transcription [73,74], thus adding a further layer of complexity in the regulation of FGFR activity (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SPROUTY interacts with GRB2 to regulate the activation of MAPK and PI3K–AKT downstream from FGFR phosphorylation [77,78] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Finally, the E3 ubiquitin ligase CBL induces the ubiquitylation of FGFR after receptor internalization and regulates the sorting of FGFR into the degradative pathway which results in signalling termination [81] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in Fgf10 knock-out mice this defect is less pronounced, owing to the redundant expression of another FGFR2b-specific ligand, FGF7 [31] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the mammary gland epithelium fails to ramify in the Fgf10 knock-out mice, where an underdeveloped mammary fat pad has also been observed [31], suggesting a role for FGF10 in the formation of adipocytes via FGFR1b signalling [86] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the several FGFs produced by the mammary gland stroma, including FGF2, FGF7, FGF9 and FGF10, regulate epithelial morphogenesis through FGFR1 and FGFR2 activation [88] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This ductal/ lobular cellular bilayer is encapsulated by the diverse cell types (immune and non-immune) of the tumour microenvironment (TME) and stromal tissue (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "10%)), using laboratory-based immunohistochemistry and/or in situ hybridization assays based on differential expression of oestrogen, progesterone and the HER2 receptor (ER, PR and HER2) (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Activation of FGFRs in breast cancer is attributed to receptor gene amplification and mutations, gene fusions resulting from translocations and amplification, and more rarely alternative splicing [3] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Schematic of breast cancer extracellular environment (from figure 1) and breast cancer epithelial cells (from figures 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The black lines on the ‘FGF’ text indicate the lack of available information on the role of those specific FGFs in breast cancer.Numerous FGF genes are amplified or show deregulated levels of transcripts and proteins and are often overexpressed in the extracellular matrix or in the stroma, all mechanisms contributing to the amplification of FGFR signalling or the inhibition of its regulatory mechanisms [113] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We will highlight their known genetic alterations, and discuss how dysregulated signalling pathways and cellular localization, and interactions with the microenvironment globally affect the behaviour of breast cancer cells (figure 4).5.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF1 subfamily: FGF1, FGF2\nThe FGF1 subfamily is composed of FGF1 (also known as acidic FGF) and of FGF2 (also known as basic FGF) (figure 2a,b), which have minor roles during development, but are crucial for tissue repair after injury in the adult and in angiogenesis [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF2 regulates tumour growth and migration in vitro and in xenograft models [125], not only by activating FGFR1 signalling [126], but also through oestrogen receptor (ER) signalling [127] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Both FGF1 and FGF2 play a crucial role in breast cancer angiogenesis [129,130] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF4 subfamily: FGF4, FGF5, FGF6\nThe FGF4 subfamily is composed of FGF4, which is crucial for early development in mice, FGF5 and FGF6, whose deletion in mice does not have a known phenotype [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF7 subfamily: FGF3, FGF7, FGF10, FGF22\nMembers of the FGF7 subfamily are FGF3, FGF7, FGF10 and FGF22 (figure 2a,b), of which FGF10 is known to be involved in the formation of mammary gland during development [2] (see §4.2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, anti-FGF3/FGFR2b therapies may benefit patients with HER2-positive breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In terms of signalling pathway activation, FGF7 binding to its receptor FGFR2b (figure 2b) also activates ERK1/2, which in turn promotes FGF7-dependent migration of ER-positive breast cancer cells [150].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF10 is also expressed exclusively by the stromal fibroblasts of normal and breast cancer tissue and has been reported to be an oncogene in mammary tumour virus mouse models and in a subset of breast carcinomas showing high expression of the protein [153,154] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This is due to the paracrine action of FGF10 on its receptor, the FGFR2b isoform, which is highly abundant on the mammary gland [157] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF8 subfamily: FGF8, FGF17, FGF18\nThe FGF8 subfamily is composed of FGF8, FGF17 and FGF18 (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF9 subfamily: FGF9, FGF16, FGF20\nMembers of the FGF9 subfamily (FGF9, FGF16, FGF20 (figure 2a,b)) regulate development at multiple levels in lungs, male germ cells, skeleton, small intestine and cardiomyocytes [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF9 is highly expressed in breast cancer compared with normal tissue, although its expression is not as high as the expression of other FGFs like FGF1 [134] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The endocrine FGFs: FGF15/19, FGF21, FGF23\nThe endocrine FGFs have several roles both during development and in the homeostasis of adult tissues [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Given the role of FGF21 in metabolism and the important relationship between metabolism and breast cancer [172], it has been suggested that monitoring the serum levels of FGF21 during anti-breast cancer therapies could be valuable, although more data are necessary to shed light on the role of FGF21 in breast cancer [173] (figure 4).5.3.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs: FGF11, FGF12, FGF13, FGF14\nMice knocked-out for intracellular FGFs (figure 2a,b) present various defects in neurons (Fgf13 and Fgf14 knock-out) and altered voltage-gated sodium channel physiology (Fgf14 knock-out) [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the same lines, the expression of a long non-coding RNA, FGF14 antisense RNA 2, was downregulated in breast compared with normal tissue, and this correlates with larger tumour size and more lymph node metastasis [175] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In vivo, resistance to CDK4/6 and to anti-HER2 treatment inhibitors can be reversed by combination with anti-FGFR drugs, such as lucitanib or erdafitinib [136,184]; this indicates the importance of targeting different pathways in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This may represent one of the mechanisms responsible for acquired resistance to the anti-HER2 drug lapatinib [187], and this finding suggests that inhibiting both FGFR1 and HER2 signalling might be beneficial for patients (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR1 signalling associated with ER in the nuclei of breast cancer cells regulates the transcription of ER-dependent genes, contributing to mechanisms of resistance in ER-positive samples [191] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The crosstalk between FGFR1 and other signalling pathways in responding to changes of the environment is also exemplified by data showing that the inhibition of both FGFR1 and VEGFR is more efficient in reducing tumour angiogenesis than either treatment alone [197,198] (figure 4).6.2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, very recently it has been reported that FGFR2 can be expressed also in ER/PR-positive tumours where, surprisingly, low FGFR2 expression correlates with poor prognosis [201] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the signalling cascades activated by FGF10 downstream of FGFR2b were reported to counteract ER-dependent signalling [156] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR2 signalling promotes HER2 shedding through the metalloprotease ADAM10 and enhances HER2 signalling, HER2-dependent proliferation and tumour progression in mouse xenografts [216] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the authors showed that FGF5 secreted by cancer-associated fibroblasts (CAF) in the microenvironment might be responsible for the high activation of FGFR2 on the neighbouring epithelial cells [137], confirming the potential signalling switch between HER2 and FGFR2 in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF7, another specific ligand for FGFR2b (figure 2a,b) has been shown to trigger phosphorylation of progesterone receptor at Ser294 and its degradation via the FGFR2–RSK2 signalling axis [151].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A potential mechanism underlying this effect is FGFR4-mediated regulation of membrane ruffling in response to both FGF1 and 2 [122] (figure 2a,b), which might increase AKT signalling.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The role of FGFR4 in liver metabolism may offer an alternative explanation to link AKT signalling and survival depending on FGFR4 signalling [222] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Given the variety of phenotypes of mice knocked-out for Fgfr isoforms [4], the differential expression and role of the ‘b’ and ‘c’ variants in tissue [61], and the possibility of trans-phosphorylation between different FGFRs [245], it is worth speculating that the landscape of dysregulated FGFR signalling is much more complex than the one presented here (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Among these RTKs, there are epidermal growth factor receptors (EGFRs), vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), insulin-like growth factor receptors (IGFRs) and FGFRs [6] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Upon ligand stimulation, RTKs activate several pathways, including mitogen-activated protein kinase (MAPK), Janus kinase (JAK)/signal transducer and activator of transcription (STAT), phospholipase C gamma (PLCγ) and phosphoinositide 3-kinase (PI3–K) [7] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RTK signalling regulates the response of cancer cells to perturbation of the extracellular environment, composed of fibroblasts, adipocytes, immune cells, and proteins of the extracellular matrix and of the extended vasculature [8] (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The different subfamilies are based on the biochemical properties, sequence similarities and evolutionary relationships of their members (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Firstly, Y653, in the activation loop, is phosphorylated, followed by the phosphorylation of Y583, Y463, Y654, Y677, Y766 and Y585, whereas Y730 is weakly phosphorylated [11–13] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FRS2α, which is constitutively associated with the receptor, is phosphorylated upon ligand binding, and recruits adaptor proteins, like GRB2, which in turn recruits SOS followed by members of the MAPK family, and GAB1, which then activates the PI3K–AKT signalling axis [15] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "By contrast, AKT induces the activation of the mTOR complex 1 [22] and the phosphorylation of the FOXO1 transcription factor [23] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Following recruitment to activated FGFR the enzyme PLCγ induces calcium ion release, resulting in the activation of downstream kinases like PKC [24] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR also activates STAT1, 3 and 5, which regulate gene expression in the nucleus [25] (figure 2c).3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFs, FGFRs and cofactors\nThe FGF family includes secreted FGFs—the FGF1, FGF4, FGF7, FGF8, FGF9 and FGF15/19 subfamilies—and intracellular FGFs—the FGF11 subfamily [26,27] (figure 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs—also known as FGF homologous factors (FHFs) (figure 2a)—serve as cofactors for members of the voltage-gated sodium channel family, mitogen-activated protein kinase 8-interacting protein 2 (MAPK8IP2), β-tubulin and NF-κB essential modulator (NEMO) [40–43].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are five FGFR genes, and FGFR1–3 can be alternatively spliced into variants of immunoglobulin-like domain III, referred to as ‘b’ and ‘c’, which are essential for ligand-binding specificity and are mainly expressed in epithelial and mesenchymal cells, respectively [4,45–47] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR1c and 3c interact with FGF2, members of the FGF4, 8 and 9 subfamilies, and with the endocrine FGFs (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR2c can bind the same FGFs as the other two mesenchymal isoforms of FGFR with the exception of the endocrine FGFs FGF21 and FGF23 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The epithelial isoforms of FGFR1 and 2, FGFR1b and 2b, are preferentially activated by the FGF7 subfamily—with FGF7 specific for FGFR2b, whereas FGFR3b interacts with the FGF8 and 9 subfamilies [49,50] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The endocrine FGF15/19 subfamily has higher affinity for the mesenchymal isoforms of FGFR1–3 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR4 is activated not only upon FGF2, 4, 6, 8, 17 and 18 binding but also by the endocrine ligands FGF15/19 and FGF23 [51] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regulatory mechanisms may occur at different levels: in the extracellular environment, at the plasma membrane, during internalization and sorting or translocation to the nucleus, and through feedback signalling mechanisms (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Other cell surface molecules, like anosmin-1, Similar Expression to Fgf (SEF), and the adhesion molecules N-cadherin or Neuronal Cell Adhesion Molecule (NCAM), can modulate FGFR signalling in different cell contexts and organs [63–67], thus enlarging the variety of extracellular modulator of FGFR signalling [10] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Similarities and differences in signalling of the four FGFRs could be also determined by sub-cellular localization (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, nuclear translocation of FGFR1 and FGFR2 has been shown to specify the behaviour of cancer cells by regulating signalling and transcription [73,74], thus adding a further layer of complexity in the regulation of FGFR activity (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SPROUTY interacts with GRB2 to regulate the activation of MAPK and PI3K–AKT downstream from FGFR phosphorylation [77,78] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Finally, the E3 ubiquitin ligase CBL induces the ubiquitylation of FGFR after receptor internalization and regulates the sorting of FGFR into the degradative pathway which results in signalling termination [81] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in Fgf10 knock-out mice this defect is less pronounced, owing to the redundant expression of another FGFR2b-specific ligand, FGF7 [31] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the mammary gland epithelium fails to ramify in the Fgf10 knock-out mice, where an underdeveloped mammary fat pad has also been observed [31], suggesting a role for FGF10 in the formation of adipocytes via FGFR1b signalling [86] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the several FGFs produced by the mammary gland stroma, including FGF2, FGF7, FGF9 and FGF10, regulate epithelial morphogenesis through FGFR1 and FGFR2 activation [88] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This ductal/ lobular cellular bilayer is encapsulated by the diverse cell types (immune and non-immune) of the tumour microenvironment (TME) and stromal tissue (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "10%)), using laboratory-based immunohistochemistry and/or in situ hybridization assays based on differential expression of oestrogen, progesterone and the HER2 receptor (ER, PR and HER2) (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Activation of FGFRs in breast cancer is attributed to receptor gene amplification and mutations, gene fusions resulting from translocations and amplification, and more rarely alternative splicing [3] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Schematic of breast cancer extracellular environment (from figure 1) and breast cancer epithelial cells (from figures 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The black lines on the ‘FGF’ text indicate the lack of available information on the role of those specific FGFs in breast cancer.Numerous FGF genes are amplified or show deregulated levels of transcripts and proteins and are often overexpressed in the extracellular matrix or in the stroma, all mechanisms contributing to the amplification of FGFR signalling or the inhibition of its regulatory mechanisms [113] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We will highlight their known genetic alterations, and discuss how dysregulated signalling pathways and cellular localization, and interactions with the microenvironment globally affect the behaviour of breast cancer cells (figure 4).5.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF1 subfamily: FGF1, FGF2\nThe FGF1 subfamily is composed of FGF1 (also known as acidic FGF) and of FGF2 (also known as basic FGF) (figure 2a,b), which have minor roles during development, but are crucial for tissue repair after injury in the adult and in angiogenesis [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF2 regulates tumour growth and migration in vitro and in xenograft models [125], not only by activating FGFR1 signalling [126], but also through oestrogen receptor (ER) signalling [127] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Both FGF1 and FGF2 play a crucial role in breast cancer angiogenesis [129,130] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF4 subfamily: FGF4, FGF5, FGF6\nThe FGF4 subfamily is composed of FGF4, which is crucial for early development in mice, FGF5 and FGF6, whose deletion in mice does not have a known phenotype [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF7 subfamily: FGF3, FGF7, FGF10, FGF22\nMembers of the FGF7 subfamily are FGF3, FGF7, FGF10 and FGF22 (figure 2a,b), of which FGF10 is known to be involved in the formation of mammary gland during development [2] (see §4.2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, anti-FGF3/FGFR2b therapies may benefit patients with HER2-positive breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In terms of signalling pathway activation, FGF7 binding to its receptor FGFR2b (figure 2b) also activates ERK1/2, which in turn promotes FGF7-dependent migration of ER-positive breast cancer cells [150].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF10 is also expressed exclusively by the stromal fibroblasts of normal and breast cancer tissue and has been reported to be an oncogene in mammary tumour virus mouse models and in a subset of breast carcinomas showing high expression of the protein [153,154] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This is due to the paracrine action of FGF10 on its receptor, the FGFR2b isoform, which is highly abundant on the mammary gland [157] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF8 subfamily: FGF8, FGF17, FGF18\nThe FGF8 subfamily is composed of FGF8, FGF17 and FGF18 (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF9 subfamily: FGF9, FGF16, FGF20\nMembers of the FGF9 subfamily (FGF9, FGF16, FGF20 (figure 2a,b)) regulate development at multiple levels in lungs, male germ cells, skeleton, small intestine and cardiomyocytes [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF9 is highly expressed in breast cancer compared with normal tissue, although its expression is not as high as the expression of other FGFs like FGF1 [134] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The endocrine FGFs: FGF15/19, FGF21, FGF23\nThe endocrine FGFs have several roles both during development and in the homeostasis of adult tissues [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Given the role of FGF21 in metabolism and the important relationship between metabolism and breast cancer [172], it has been suggested that monitoring the serum levels of FGF21 during anti-breast cancer therapies could be valuable, although more data are necessary to shed light on the role of FGF21 in breast cancer [173] (figure 4).5.3.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs: FGF11, FGF12, FGF13, FGF14\nMice knocked-out for intracellular FGFs (figure 2a,b) present various defects in neurons (Fgf13 and Fgf14 knock-out) and altered voltage-gated sodium channel physiology (Fgf14 knock-out) [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the same lines, the expression of a long non-coding RNA, FGF14 antisense RNA 2, was downregulated in breast compared with normal tissue, and this correlates with larger tumour size and more lymph node metastasis [175] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In vivo, resistance to CDK4/6 and to anti-HER2 treatment inhibitors can be reversed by combination with anti-FGFR drugs, such as lucitanib or erdafitinib [136,184]; this indicates the importance of targeting different pathways in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This may represent one of the mechanisms responsible for acquired resistance to the anti-HER2 drug lapatinib [187], and this finding suggests that inhibiting both FGFR1 and HER2 signalling might be beneficial for patients (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR1 signalling associated with ER in the nuclei of breast cancer cells regulates the transcription of ER-dependent genes, contributing to mechanisms of resistance in ER-positive samples [191] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The crosstalk between FGFR1 and other signalling pathways in responding to changes of the environment is also exemplified by data showing that the inhibition of both FGFR1 and VEGFR is more efficient in reducing tumour angiogenesis than either treatment alone [197,198] (figure 4).6.2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, very recently it has been reported that FGFR2 can be expressed also in ER/PR-positive tumours where, surprisingly, low FGFR2 expression correlates with poor prognosis [201] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the signalling cascades activated by FGF10 downstream of FGFR2b were reported to counteract ER-dependent signalling [156] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR2 signalling promotes HER2 shedding through the metalloprotease ADAM10 and enhances HER2 signalling, HER2-dependent proliferation and tumour progression in mouse xenografts [216] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the authors showed that FGF5 secreted by cancer-associated fibroblasts (CAF) in the microenvironment might be responsible for the high activation of FGFR2 on the neighbouring epithelial cells [137], confirming the potential signalling switch between HER2 and FGFR2 in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF7, another specific ligand for FGFR2b (figure 2a,b) has been shown to trigger phosphorylation of progesterone receptor at Ser294 and its degradation via the FGFR2–RSK2 signalling axis [151].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A potential mechanism underlying this effect is FGFR4-mediated regulation of membrane ruffling in response to both FGF1 and 2 [122] (figure 2a,b), which might increase AKT signalling.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The role of FGFR4 in liver metabolism may offer an alternative explanation to link AKT signalling and survival depending on FGFR4 signalling [222] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Given the variety of phenotypes of mice knocked-out for Fgfr isoforms [4], the differential expression and role of the ‘b’ and ‘c’ variants in tissue [61], and the possibility of trans-phosphorylation between different FGFRs [245], it is worth speculating that the landscape of dysregulated FGFR signalling is much more complex than the one presented here (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Among these RTKs, there are epidermal growth factor receptors (EGFRs), vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), insulin-like growth factor receptors (IGFRs) and FGFRs [6] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Upon ligand stimulation, RTKs activate several pathways, including mitogen-activated protein kinase (MAPK), Janus kinase (JAK)/signal transducer and activator of transcription (STAT), phospholipase C gamma (PLCγ) and phosphoinositide 3-kinase (PI3–K) [7] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RTK signalling regulates the response of cancer cells to perturbation of the extracellular environment, composed of fibroblasts, adipocytes, immune cells, and proteins of the extracellular matrix and of the extended vasculature [8] (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The different subfamilies are based on the biochemical properties, sequence similarities and evolutionary relationships of their members (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Firstly, Y653, in the activation loop, is phosphorylated, followed by the phosphorylation of Y583, Y463, Y654, Y677, Y766 and Y585, whereas Y730 is weakly phosphorylated [11–13] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FRS2α, which is constitutively associated with the receptor, is phosphorylated upon ligand binding, and recruits adaptor proteins, like GRB2, which in turn recruits SOS followed by members of the MAPK family, and GAB1, which then activates the PI3K–AKT signalling axis [15] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "By contrast, AKT induces the activation of the mTOR complex 1 [22] and the phosphorylation of the FOXO1 transcription factor [23] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Following recruitment to activated FGFR the enzyme PLCγ induces calcium ion release, resulting in the activation of downstream kinases like PKC [24] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR also activates STAT1, 3 and 5, which regulate gene expression in the nucleus [25] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Among these RTKs, there are epidermal growth factor receptors (EGFRs), vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), insulin-like growth factor receptors (IGFRs) and FGFRs [6] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Upon ligand stimulation, RTKs activate several pathways, including mitogen-activated protein kinase (MAPK), Janus kinase (JAK)/signal transducer and activator of transcription (STAT), phospholipase C gamma (PLCγ) and phosphoinositide 3-kinase (PI3–K) [7] (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RTK signalling regulates the response of cancer cells to perturbation of the extracellular environment, composed of fibroblasts, adipocytes, immune cells, and proteins of the extracellular matrix and of the extended vasculature [8] (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The different subfamilies are based on the biochemical properties, sequence similarities and evolutionary relationships of their members (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Firstly, Y653, in the activation loop, is phosphorylated, followed by the phosphorylation of Y583, Y463, Y654, Y677, Y766 and Y585, whereas Y730 is weakly phosphorylated [11–13] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FRS2α, which is constitutively associated with the receptor, is phosphorylated upon ligand binding, and recruits adaptor proteins, like GRB2, which in turn recruits SOS followed by members of the MAPK family, and GAB1, which then activates the PI3K–AKT signalling axis [15] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "By contrast, AKT induces the activation of the mTOR complex 1 [22] and the phosphorylation of the FOXO1 transcription factor [23] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Following recruitment to activated FGFR the enzyme PLCγ induces calcium ion release, resulting in the activation of downstream kinases like PKC [24] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR also activates STAT1, 3 and 5, which regulate gene expression in the nucleus [25] (figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFs, FGFRs and cofactors\nThe FGF family includes secreted FGFs—the FGF1, FGF4, FGF7, FGF8, FGF9 and FGF15/19 subfamilies—and intracellular FGFs—the FGF11 subfamily [26,27] (figure 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs—also known as FGF homologous factors (FHFs) (figure 2a)—serve as cofactors for members of the voltage-gated sodium channel family, mitogen-activated protein kinase 8-interacting protein 2 (MAPK8IP2), β-tubulin and NF-κB essential modulator (NEMO) [40–43].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are five FGFR genes, and FGFR1–3 can be alternatively spliced into variants of immunoglobulin-like domain III, referred to as ‘b’ and ‘c’, which are essential for ligand-binding specificity and are mainly expressed in epithelial and mesenchymal cells, respectively [4,45–47] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR1c and 3c interact with FGF2, members of the FGF4, 8 and 9 subfamilies, and with the endocrine FGFs (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR2c can bind the same FGFs as the other two mesenchymal isoforms of FGFR with the exception of the endocrine FGFs FGF21 and FGF23 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The epithelial isoforms of FGFR1 and 2, FGFR1b and 2b, are preferentially activated by the FGF7 subfamily—with FGF7 specific for FGFR2b, whereas FGFR3b interacts with the FGF8 and 9 subfamilies [49,50] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The endocrine FGF15/19 subfamily has higher affinity for the mesenchymal isoforms of FGFR1–3 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR4 is activated not only upon FGF2, 4, 6, 8, 17 and 18 binding but also by the endocrine ligands FGF15/19 and FGF23 [51] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF family includes secreted FGFs—the FGF1, FGF4, FGF7, FGF8, FGF9 and FGF15/19 subfamilies—and intracellular FGFs—the FGF11 subfamily [26,27] (figure 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs—also known as FGF homologous factors (FHFs) (figure 2a)—serve as cofactors for members of the voltage-gated sodium channel family, mitogen-activated protein kinase 8-interacting protein 2 (MAPK8IP2), β-tubulin and NF-κB essential modulator (NEMO) [40–43].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are five FGFR genes, and FGFR1–3 can be alternatively spliced into variants of immunoglobulin-like domain III, referred to as ‘b’ and ‘c’, which are essential for ligand-binding specificity and are mainly expressed in epithelial and mesenchymal cells, respectively [4,45–47] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR1c and 3c interact with FGF2, members of the FGF4, 8 and 9 subfamilies, and with the endocrine FGFs (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGFR2c can bind the same FGFs as the other two mesenchymal isoforms of FGFR with the exception of the endocrine FGFs FGF21 and FGF23 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The epithelial isoforms of FGFR1 and 2, FGFR1b and 2b, are preferentially activated by the FGF7 subfamily—with FGF7 specific for FGFR2b, whereas FGFR3b interacts with the FGF8 and 9 subfamilies [49,50] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The endocrine FGF15/19 subfamily has higher affinity for the mesenchymal isoforms of FGFR1–3 [4] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Finally, FGFR4 is activated not only upon FGF2, 4, 6, 8, 17 and 18 binding but also by the endocrine ligands FGF15/19 and FGF23 [51] (figure 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regulatory mechanisms may occur at different levels: in the extracellular environment, at the plasma membrane, during internalization and sorting or translocation to the nucleus, and through feedback signalling mechanisms (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Other cell surface molecules, like anosmin-1, Similar Expression to Fgf (SEF), and the adhesion molecules N-cadherin or Neuronal Cell Adhesion Molecule (NCAM), can modulate FGFR signalling in different cell contexts and organs [63–67], thus enlarging the variety of extracellular modulator of FGFR signalling [10] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Similarities and differences in signalling of the four FGFRs could be also determined by sub-cellular localization (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, nuclear translocation of FGFR1 and FGFR2 has been shown to specify the behaviour of cancer cells by regulating signalling and transcription [73,74], thus adding a further layer of complexity in the regulation of FGFR activity (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SPROUTY interacts with GRB2 to regulate the activation of MAPK and PI3K–AKT downstream from FGFR phosphorylation [77,78] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Finally, the E3 ubiquitin ligase CBL induces the ubiquitylation of FGFR after receptor internalization and regulates the sorting of FGFR into the degradative pathway which results in signalling termination [81] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in Fgf10 knock-out mice this defect is less pronounced, owing to the redundant expression of another FGFR2b-specific ligand, FGF7 [31] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the mammary gland epithelium fails to ramify in the Fgf10 knock-out mice, where an underdeveloped mammary fat pad has also been observed [31], suggesting a role for FGF10 in the formation of adipocytes via FGFR1b signalling [86] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the several FGFs produced by the mammary gland stroma, including FGF2, FGF7, FGF9 and FGF10, regulate epithelial morphogenesis through FGFR1 and FGFR2 activation [88] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This ductal/ lobular cellular bilayer is encapsulated by the diverse cell types (immune and non-immune) of the tumour microenvironment (TME) and stromal tissue (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "10%)), using laboratory-based immunohistochemistry and/or in situ hybridization assays based on differential expression of oestrogen, progesterone and the HER2 receptor (ER, PR and HER2) (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Activation of FGFRs in breast cancer is attributed to receptor gene amplification and mutations, gene fusions resulting from translocations and amplification, and more rarely alternative splicing [3] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Schematic of breast cancer extracellular environment (from figure 1) and breast cancer epithelial cells (from figures 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The black lines on the ‘FGF’ text indicate the lack of available information on the role of those specific FGFs in breast cancer.Numerous FGF genes are amplified or show deregulated levels of transcripts and proteins and are often overexpressed in the extracellular matrix or in the stroma, all mechanisms contributing to the amplification of FGFR signalling or the inhibition of its regulatory mechanisms [113] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We will highlight their known genetic alterations, and discuss how dysregulated signalling pathways and cellular localization, and interactions with the microenvironment globally affect the behaviour of breast cancer cells (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Regulatory mechanisms may occur at different levels: in the extracellular environment, at the plasma membrane, during internalization and sorting or translocation to the nucleus, and through feedback signalling mechanisms (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Other cell surface molecules, like anosmin-1, Similar Expression to Fgf (SEF), and the adhesion molecules N-cadherin or Neuronal Cell Adhesion Molecule (NCAM), can modulate FGFR signalling in different cell contexts and organs [63–67], thus enlarging the variety of extracellular modulator of FGFR signalling [10] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Similarities and differences in signalling of the four FGFRs could be also determined by sub-cellular localization (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, nuclear translocation of FGFR1 and FGFR2 has been shown to specify the behaviour of cancer cells by regulating signalling and transcription [73,74], thus adding a further layer of complexity in the regulation of FGFR activity (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SPROUTY interacts with GRB2 to regulate the activation of MAPK and PI3K–AKT downstream from FGFR phosphorylation [77,78] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Finally, the E3 ubiquitin ligase CBL induces the ubiquitylation of FGFR after receptor internalization and regulates the sorting of FGFR into the degradative pathway which results in signalling termination [81] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Regulatory mechanisms may occur at different levels: in the extracellular environment, at the plasma membrane, during internalization and sorting or translocation to the nucleus, and through feedback signalling mechanisms (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Other cell surface molecules, like anosmin-1, Similar Expression to Fgf (SEF), and the adhesion molecules N-cadherin or Neuronal Cell Adhesion Molecule (NCAM), can modulate FGFR signalling in different cell contexts and organs [63–67], thus enlarging the variety of extracellular modulator of FGFR signalling [10] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Similarities and differences in signalling of the four FGFRs could be also determined by sub-cellular localization (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, nuclear translocation of FGFR1 and FGFR2 has been shown to specify the behaviour of cancer cells by regulating signalling and transcription [73,74], thus adding a further layer of complexity in the regulation of FGFR activity (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SPROUTY interacts with GRB2 to regulate the activation of MAPK and PI3K–AKT downstream from FGFR phosphorylation [77,78] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Finally, the E3 ubiquitin ligase CBL induces the ubiquitylation of FGFR after receptor internalization and regulates the sorting of FGFR into the degradative pathway which results in signalling termination [81] (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in Fgf10 knock-out mice this defect is less pronounced, owing to the redundant expression of another FGFR2b-specific ligand, FGF7 [31] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the mammary gland epithelium fails to ramify in the Fgf10 knock-out mice, where an underdeveloped mammary fat pad has also been observed [31], suggesting a role for FGF10 in the formation of adipocytes via FGFR1b signalling [86] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the several FGFs produced by the mammary gland stroma, including FGF2, FGF7, FGF9 and FGF10, regulate epithelial morphogenesis through FGFR1 and FGFR2 activation [88] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "However, in Fgf10 knock-out mice this defect is less pronounced, owing to the redundant expression of another FGFR2b-specific ligand, FGF7 [31] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the mammary gland epithelium fails to ramify in the Fgf10 knock-out mice, where an underdeveloped mammary fat pad has also been observed [31], suggesting a role for FGF10 in the formation of adipocytes via FGFR1b signalling [86] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, the several FGFs produced by the mammary gland stroma, including FGF2, FGF7, FGF9 and FGF10, regulate epithelial morphogenesis through FGFR1 and FGFR2 activation [88] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This ductal/ lobular cellular bilayer is encapsulated by the diverse cell types (immune and non-immune) of the tumour microenvironment (TME) and stromal tissue (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "10%)), using laboratory-based immunohistochemistry and/or in situ hybridization assays based on differential expression of oestrogen, progesterone and the HER2 receptor (ER, PR and HER2) (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Activation of FGFRs in breast cancer is attributed to receptor gene amplification and mutations, gene fusions resulting from translocations and amplification, and more rarely alternative splicing [3] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Schematic of breast cancer extracellular environment (from figure 1) and breast cancer epithelial cells (from figures 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The black lines on the ‘FGF’ text indicate the lack of available information on the role of those specific FGFs in breast cancer.Numerous FGF genes are amplified or show deregulated levels of transcripts and proteins and are often overexpressed in the extracellular matrix or in the stroma, all mechanisms contributing to the amplification of FGFR signalling or the inhibition of its regulatory mechanisms [113] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We will highlight their known genetic alterations, and discuss how dysregulated signalling pathways and cellular localization, and interactions with the microenvironment globally affect the behaviour of breast cancer cells (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This ductal/ lobular cellular bilayer is encapsulated by the diverse cell types (immune and non-immune) of the tumour microenvironment (TME) and stromal tissue (figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "10%)), using laboratory-based immunohistochemistry and/or in situ hybridization assays based on differential expression of oestrogen, progesterone and the HER2 receptor (ER, PR and HER2) (figure 1a).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Activation of FGFRs in breast cancer is attributed to receptor gene amplification and mutations, gene fusions resulting from translocations and amplification, and more rarely alternative splicing [3] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Schematic of breast cancer extracellular environment (from figure 1) and breast cancer epithelial cells (from figures 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Numerous FGF genes are amplified or show deregulated levels of transcripts and proteins and are often overexpressed in the extracellular matrix or in the stroma, all mechanisms contributing to the amplification of FGFR signalling or the inhibition of its regulatory mechanisms [113] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We will highlight their known genetic alterations, and discuss how dysregulated signalling pathways and cellular localization, and interactions with the microenvironment globally affect the behaviour of breast cancer cells (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF1 subfamily: FGF1, FGF2\nThe FGF1 subfamily is composed of FGF1 (also known as acidic FGF) and of FGF2 (also known as basic FGF) (figure 2a,b), which have minor roles during development, but are crucial for tissue repair after injury in the adult and in angiogenesis [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF2 regulates tumour growth and migration in vitro and in xenograft models [125], not only by activating FGFR1 signalling [126], but also through oestrogen receptor (ER) signalling [127] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Both FGF1 and FGF2 play a crucial role in breast cancer angiogenesis [129,130] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF4 subfamily: FGF4, FGF5, FGF6\nThe FGF4 subfamily is composed of FGF4, which is crucial for early development in mice, FGF5 and FGF6, whose deletion in mice does not have a known phenotype [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF7 subfamily: FGF3, FGF7, FGF10, FGF22\nMembers of the FGF7 subfamily are FGF3, FGF7, FGF10 and FGF22 (figure 2a,b), of which FGF10 is known to be involved in the formation of mammary gland during development [2] (see §4.2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, anti-FGF3/FGFR2b therapies may benefit patients with HER2-positive breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In terms of signalling pathway activation, FGF7 binding to its receptor FGFR2b (figure 2b) also activates ERK1/2, which in turn promotes FGF7-dependent migration of ER-positive breast cancer cells [150].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF10 is also expressed exclusively by the stromal fibroblasts of normal and breast cancer tissue and has been reported to be an oncogene in mammary tumour virus mouse models and in a subset of breast carcinomas showing high expression of the protein [153,154] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This is due to the paracrine action of FGF10 on its receptor, the FGFR2b isoform, which is highly abundant on the mammary gland [157] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF8 subfamily: FGF8, FGF17, FGF18\nThe FGF8 subfamily is composed of FGF8, FGF17 and FGF18 (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF9 subfamily: FGF9, FGF16, FGF20\nMembers of the FGF9 subfamily (FGF9, FGF16, FGF20 (figure 2a,b)) regulate development at multiple levels in lungs, male germ cells, skeleton, small intestine and cardiomyocytes [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF9 is highly expressed in breast cancer compared with normal tissue, although its expression is not as high as the expression of other FGFs like FGF1 [134] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The endocrine FGFs: FGF15/19, FGF21, FGF23\nThe endocrine FGFs have several roles both during development and in the homeostasis of adult tissues [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Given the role of FGF21 in metabolism and the important relationship between metabolism and breast cancer [172], it has been suggested that monitoring the serum levels of FGF21 during anti-breast cancer therapies could be valuable, although more data are necessary to shed light on the role of FGF21 in breast cancer [173] (figure 4).5.3.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs: FGF11, FGF12, FGF13, FGF14\nMice knocked-out for intracellular FGFs (figure 2a,b) present various defects in neurons (Fgf13 and Fgf14 knock-out) and altered voltage-gated sodium channel physiology (Fgf14 knock-out) [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the same lines, the expression of a long non-coding RNA, FGF14 antisense RNA 2, was downregulated in breast compared with normal tissue, and this correlates with larger tumour size and more lymph node metastasis [175] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF1 subfamily: FGF1, FGF2\nThe FGF1 subfamily is composed of FGF1 (also known as acidic FGF) and of FGF2 (also known as basic FGF) (figure 2a,b), which have minor roles during development, but are crucial for tissue repair after injury in the adult and in angiogenesis [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF2 regulates tumour growth and migration in vitro and in xenograft models [125], not only by activating FGFR1 signalling [126], but also through oestrogen receptor (ER) signalling [127] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Both FGF1 and FGF2 play a crucial role in breast cancer angiogenesis [129,130] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF4 subfamily: FGF4, FGF5, FGF6\nThe FGF4 subfamily is composed of FGF4, which is crucial for early development in mice, FGF5 and FGF6, whose deletion in mice does not have a known phenotype [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF7 subfamily: FGF3, FGF7, FGF10, FGF22\nMembers of the FGF7 subfamily are FGF3, FGF7, FGF10 and FGF22 (figure 2a,b), of which FGF10 is known to be involved in the formation of mammary gland during development [2] (see §4.2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, anti-FGF3/FGFR2b therapies may benefit patients with HER2-positive breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In terms of signalling pathway activation, FGF7 binding to its receptor FGFR2b (figure 2b) also activates ERK1/2, which in turn promotes FGF7-dependent migration of ER-positive breast cancer cells [150].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF10 is also expressed exclusively by the stromal fibroblasts of normal and breast cancer tissue and has been reported to be an oncogene in mammary tumour virus mouse models and in a subset of breast carcinomas showing high expression of the protein [153,154] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This is due to the paracrine action of FGF10 on its receptor, the FGFR2b isoform, which is highly abundant on the mammary gland [157] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF8 subfamily: FGF8, FGF17, FGF18\nThe FGF8 subfamily is composed of FGF8, FGF17 and FGF18 (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF9 subfamily: FGF9, FGF16, FGF20\nMembers of the FGF9 subfamily (FGF9, FGF16, FGF20 (figure 2a,b)) regulate development at multiple levels in lungs, male germ cells, skeleton, small intestine and cardiomyocytes [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF9 is highly expressed in breast cancer compared with normal tissue, although its expression is not as high as the expression of other FGFs like FGF1 [134] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF1 subfamily: FGF1, FGF2\nThe FGF1 subfamily is composed of FGF1 (also known as acidic FGF) and of FGF2 (also known as basic FGF) (figure 2a,b), which have minor roles during development, but are crucial for tissue repair after injury in the adult and in angiogenesis [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF2 regulates tumour growth and migration in vitro and in xenograft models [125], not only by activating FGFR1 signalling [126], but also through oestrogen receptor (ER) signalling [127] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Both FGF1 and FGF2 play a crucial role in breast cancer angiogenesis [129,130] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF1 subfamily is composed of FGF1 (also known as acidic FGF) and of FGF2 (also known as basic FGF) (figure 2a,b), which have minor roles during development, but are crucial for tissue repair after injury in the adult and in angiogenesis [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF2 regulates tumour growth and migration in vitro and in xenograft models [125], not only by activating FGFR1 signalling [126], but also through oestrogen receptor (ER) signalling [127] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Both FGF1 and FGF2 play a crucial role in breast cancer angiogenesis [129,130] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The FGF4 subfamily: FGF4, FGF5, FGF6\nThe FGF4 subfamily is composed of FGF4, which is crucial for early development in mice, FGF5 and FGF6, whose deletion in mice does not have a known phenotype [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF4 subfamily is composed of FGF4, which is crucial for early development in mice, FGF5 and FGF6, whose deletion in mice does not have a known phenotype [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF7 subfamily: FGF3, FGF7, FGF10, FGF22\nMembers of the FGF7 subfamily are FGF3, FGF7, FGF10 and FGF22 (figure 2a,b), of which FGF10 is known to be involved in the formation of mammary gland during development [2] (see §4.2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, anti-FGF3/FGFR2b therapies may benefit patients with HER2-positive breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In terms of signalling pathway activation, FGF7 binding to its receptor FGFR2b (figure 2b) also activates ERK1/2, which in turn promotes FGF7-dependent migration of ER-positive breast cancer cells [150].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF10 is also expressed exclusively by the stromal fibroblasts of normal and breast cancer tissue and has been reported to be an oncogene in mammary tumour virus mouse models and in a subset of breast carcinomas showing high expression of the protein [153,154] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This is due to the paracrine action of FGF10 on its receptor, the FGFR2b isoform, which is highly abundant on the mammary gland [157] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Members of the FGF7 subfamily are FGF3, FGF7, FGF10 and FGF22 (figure 2a,b), of which FGF10 is known to be involved in the formation of mammary gland during development [2] (see §4.2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, anti-FGF3/FGFR2b therapies may benefit patients with HER2-positive breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In terms of signalling pathway activation, FGF7 binding to its receptor FGFR2b (figure 2b) also activates ERK1/2, which in turn promotes FGF7-dependent migration of ER-positive breast cancer cells [150].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "FGF10 is also expressed exclusively by the stromal fibroblasts of normal and breast cancer tissue and has been reported to be an oncogene in mammary tumour virus mouse models and in a subset of breast carcinomas showing high expression of the protein [153,154] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This is due to the paracrine action of FGF10 on its receptor, the FGFR2b isoform, which is highly abundant on the mammary gland [157] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF8 subfamily: FGF8, FGF17, FGF18\nThe FGF8 subfamily is composed of FGF8, FGF17 and FGF18 (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF8 subfamily is composed of FGF8, FGF17 and FGF18 (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The FGF9 subfamily: FGF9, FGF16, FGF20\nMembers of the FGF9 subfamily (FGF9, FGF16, FGF20 (figure 2a,b)) regulate development at multiple levels in lungs, male germ cells, skeleton, small intestine and cardiomyocytes [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF9 is highly expressed in breast cancer compared with normal tissue, although its expression is not as high as the expression of other FGFs like FGF1 [134] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Members of the FGF9 subfamily (FGF9, FGF16, FGF20 (figure 2a,b)) regulate development at multiple levels in lungs, male germ cells, skeleton, small intestine and cardiomyocytes [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF9 is highly expressed in breast cancer compared with normal tissue, although its expression is not as high as the expression of other FGFs like FGF1 [134] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The endocrine FGFs: FGF15/19, FGF21, FGF23\nThe endocrine FGFs have several roles both during development and in the homeostasis of adult tissues [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Given the role of FGF21 in metabolism and the important relationship between metabolism and breast cancer [172], it has been suggested that monitoring the serum levels of FGF21 during anti-breast cancer therapies could be valuable, although more data are necessary to shed light on the role of FGF21 in breast cancer [173] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The endocrine FGFs have several roles both during development and in the homeostasis of adult tissues [4] (figure 2a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Given the role of FGF21 in metabolism and the important relationship between metabolism and breast cancer [172], it has been suggested that monitoring the serum levels of FGF21 during anti-breast cancer therapies could be valuable, although more data are necessary to shed light on the role of FGF21 in breast cancer [173] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The intracellular FGFs: FGF11, FGF12, FGF13, FGF14\nMice knocked-out for intracellular FGFs (figure 2a,b) present various defects in neurons (Fgf13 and Fgf14 knock-out) and altered voltage-gated sodium channel physiology (Fgf14 knock-out) [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the same lines, the expression of a long non-coding RNA, FGF14 antisense RNA 2, was downregulated in breast compared with normal tissue, and this correlates with larger tumour size and more lymph node metastasis [175] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Mice knocked-out for intracellular FGFs (figure 2a,b) present various defects in neurons (Fgf13 and Fgf14 knock-out) and altered voltage-gated sodium channel physiology (Fgf14 knock-out) [4].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the same lines, the expression of a long non-coding RNA, FGF14 antisense RNA 2, was downregulated in breast compared with normal tissue, and this correlates with larger tumour size and more lymph node metastasis [175] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In vivo, resistance to CDK4/6 and to anti-HER2 treatment inhibitors can be reversed by combination with anti-FGFR drugs, such as lucitanib or erdafitinib [136,184]; this indicates the importance of targeting different pathways in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This may represent one of the mechanisms responsible for acquired resistance to the anti-HER2 drug lapatinib [187], and this finding suggests that inhibiting both FGFR1 and HER2 signalling might be beneficial for patients (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR1 signalling associated with ER in the nuclei of breast cancer cells regulates the transcription of ER-dependent genes, contributing to mechanisms of resistance in ER-positive samples [191] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The crosstalk between FGFR1 and other signalling pathways in responding to changes of the environment is also exemplified by data showing that the inhibition of both FGFR1 and VEGFR is more efficient in reducing tumour angiogenesis than either treatment alone [197,198] (figure 4).6.2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, very recently it has been reported that FGFR2 can be expressed also in ER/PR-positive tumours where, surprisingly, low FGFR2 expression correlates with poor prognosis [201] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the signalling cascades activated by FGF10 downstream of FGFR2b were reported to counteract ER-dependent signalling [156] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR2 signalling promotes HER2 shedding through the metalloprotease ADAM10 and enhances HER2 signalling, HER2-dependent proliferation and tumour progression in mouse xenografts [216] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the authors showed that FGF5 secreted by cancer-associated fibroblasts (CAF) in the microenvironment might be responsible for the high activation of FGFR2 on the neighbouring epithelial cells [137], confirming the potential signalling switch between HER2 and FGFR2 in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF7, another specific ligand for FGFR2b (figure 2a,b) has been shown to trigger phosphorylation of progesterone receptor at Ser294 and its degradation via the FGFR2–RSK2 signalling axis [151].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A potential mechanism underlying this effect is FGFR4-mediated regulation of membrane ruffling in response to both FGF1 and 2 [122] (figure 2a,b), which might increase AKT signalling.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The role of FGFR4 in liver metabolism may offer an alternative explanation to link AKT signalling and survival depending on FGFR4 signalling [222] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In vivo, resistance to CDK4/6 and to anti-HER2 treatment inhibitors can be reversed by combination with anti-FGFR drugs, such as lucitanib or erdafitinib [136,184]; this indicates the importance of targeting different pathways in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This may represent one of the mechanisms responsible for acquired resistance to the anti-HER2 drug lapatinib [187], and this finding suggests that inhibiting both FGFR1 and HER2 signalling might be beneficial for patients (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR1 signalling associated with ER in the nuclei of breast cancer cells regulates the transcription of ER-dependent genes, contributing to mechanisms of resistance in ER-positive samples [191] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The crosstalk between FGFR1 and other signalling pathways in responding to changes of the environment is also exemplified by data showing that the inhibition of both FGFR1 and VEGFR is more efficient in reducing tumour angiogenesis than either treatment alone [197,198] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In vivo, resistance to CDK4/6 and to anti-HER2 treatment inhibitors can be reversed by combination with anti-FGFR drugs, such as lucitanib or erdafitinib [136,184]; this indicates the importance of targeting different pathways in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This may represent one of the mechanisms responsible for acquired resistance to the anti-HER2 drug lapatinib [187], and this finding suggests that inhibiting both FGFR1 and HER2 signalling might be beneficial for patients (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR1 signalling associated with ER in the nuclei of breast cancer cells regulates the transcription of ER-dependent genes, contributing to mechanisms of resistance in ER-positive samples [191] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The crosstalk between FGFR1 and other signalling pathways in responding to changes of the environment is also exemplified by data showing that the inhibition of both FGFR1 and VEGFR is more efficient in reducing tumour angiogenesis than either treatment alone [197,198] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, very recently it has been reported that FGFR2 can be expressed also in ER/PR-positive tumours where, surprisingly, low FGFR2 expression correlates with poor prognosis [201] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the signalling cascades activated by FGF10 downstream of FGFR2b were reported to counteract ER-dependent signalling [156] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR2 signalling promotes HER2 shedding through the metalloprotease ADAM10 and enhances HER2 signalling, HER2-dependent proliferation and tumour progression in mouse xenografts [216] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the authors showed that FGF5 secreted by cancer-associated fibroblasts (CAF) in the microenvironment might be responsible for the high activation of FGFR2 on the neighbouring epithelial cells [137], confirming the potential signalling switch between HER2 and FGFR2 in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF7, another specific ligand for FGFR2b (figure 2a,b) has been shown to trigger phosphorylation of progesterone receptor at Ser294 and its degradation via the FGFR2–RSK2 signalling axis [151].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "However, very recently it has been reported that FGFR2 can be expressed also in ER/PR-positive tumours where, surprisingly, low FGFR2 expression correlates with poor prognosis [201] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the signalling cascades activated by FGF10 downstream of FGFR2b were reported to counteract ER-dependent signalling [156] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "FGFR2 signalling promotes HER2 shedding through the metalloprotease ADAM10 and enhances HER2 signalling, HER2-dependent proliferation and tumour progression in mouse xenografts [216] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the authors showed that FGF5 secreted by cancer-associated fibroblasts (CAF) in the microenvironment might be responsible for the high activation of FGFR2 on the neighbouring epithelial cells [137], confirming the potential signalling switch between HER2 and FGFR2 in breast cancer (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "On the contrary, FGF7, another specific ligand for FGFR2b (figure 2a,b) has been shown to trigger phosphorylation of progesterone receptor at Ser294 and its degradation via the FGFR2–RSK2 signalling axis [151].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A potential mechanism underlying this effect is FGFR4-mediated regulation of membrane ruffling in response to both FGF1 and 2 [122] (figure 2a,b), which might increase AKT signalling.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The role of FGFR4 in liver metabolism may offer an alternative explanation to link AKT signalling and survival depending on FGFR4 signalling [222] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "A potential mechanism underlying this effect is FGFR4-mediated regulation of membrane ruffling in response to both FGF1 and 2 [122] (figure 2a,b), which might increase AKT signalling.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The role of FGFR4 in liver metabolism may offer an alternative explanation to link AKT signalling and survival depending on FGFR4 signalling [222] (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Given the variety of phenotypes of mice knocked-out for Fgfr isoforms [4], the differential expression and role of the ‘b’ and ‘c’ variants in tissue [61], and the possibility of trans-phosphorylation between different FGFRs [245], it is worth speculating that the landscape of dysregulated FGFR signalling is much more complex than the one presented here (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Given the variety of phenotypes of mice knocked-out for Fgfr isoforms [4], the differential expression and role of the ‘b’ and ‘c’ variants in tissue [61], and the possibility of trans-phosphorylation between different FGFRs [245], it is worth speculating that the landscape of dysregulated FGFR signalling is much more complex than the one presented here (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Given the variety of phenotypes of mice knocked-out for Fgfr isoforms [4], the differential expression and role of the ‘b’ and ‘c’ variants in tissue [61], and the possibility of trans-phosphorylation between different FGFRs [245], it is worth speculating that the landscape of dysregulated FGFR signalling is much more complex than the one presented here (figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  }
]